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Self-assembling peptide and protein amyloids: from structure to 
tailored function in nanotechnology 
Gang Wei,a† Zhiqiang Su,b† Nicholas P. Reynolds,c Paolo Arosio,d Ian W. Hamley,e Ehud Gazitf and 
Raffaele Mezzengag,* 
Self-assembled peptide and protein amyloid nanostructures have traditionally been considered only as pathological 
aggregates implicated in human neurodegenerative diseases. In more recent times these nanostructures have found 
interesting applications as advanced materials in biomedicine, tissue engineering, renewable energy, environmental 
science, nanotechnology and material science, to name only a few fields. In all these applications, the final function 
depends on: i) the specific mechanisms of protein aggregation, ii) the hierarchical structure of the protein and peptide 
amyloids from atomistic to mesoscopic length scales, and iii) the physical properties of the amyloids in the context of their 
surrounding environment (biological or artificial). In this review we will discuss recent progress made in the field of 
functional and artificial amyloids and highlight connections between protein/peptide folding, unfolding, and aggregation 
mechanisms, with resulting amyloid structure and functionality. We also highlight current advances in the design and 
synthesis of amyloid-based biological and functional materials and identify new potential fields in which amyloid-based 
structures promise new breakthroughs. 
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1. Introduction 
The self-assembly and aggregation of peptides and proteins play 
crucial roles in many of the human’s body functions.1 For instance, 
networks of collagen fibrils provide a biochemical scaffold with 
many functions governing the morphology and mechanical 
properties of biological tissue.2, 3 Self-assembled actin fibrils are 
essential elements for many key functions in eukaryotic cells, such 
as motility, morphology, maintenance of cell polarity and the 
regulation of transcription.4 In blood coagulation, wound healing 
proceeds through aggregation of fibrin into sealing clots, allowing 
tissue repair. In addition, there are a number of diseases associated 
with errant protein aggregation. The misfolding of proteins and 
their subsequent assembly into amyloid fibrils  are pathological 
hallmarks of a number of devastating degenerative diseases, 
including Parkinson’s, Alzheimer’s, type II diabetes, and others.5  
 Historically, due to the discovery of their association with 
disease states, the study of amyloid fibrils has been largely centred 
on those associated with neurodegenerative disorders. A great deal 
of research has been performed to elucidate formation mechanisms 
and to understand mechanisms of toxicity arising from various 
amyloid species ranging from oligomers to mature amyloid 
nanofibrils.6 Consequently, a large number of biomedical studies 
have been devoted to uncovering how to inhibit amyloid formation, 
and a multitude of biomedical, biochemical, biophysical, and 
nanotechnological processes have been investigated in an attempt 
to design therapies that can slow down the progress of amyloid-
related diseases.7-10  
 The discovery that functional amyloid fibrils in living organisms 
also play vital physiological roles within and on the surface of living 
cells has introduced a new paradigm for the study of amyloid fibrils. 
Examples of the physiological roles of functional amyloids include, 
curli fibrils,11 associated with the adhesive properties of E. Coli 
biofilms, catalysis of melanin synthesis in mammalian 
melanosomes,12 and human peptide hormone storage.13  
 In addition to toxic and functional amyloids, in recent years 
there has been a growing interest in the applications of amyloid 
fibrils as templates or building blocks in ordered nanomaterials for 
biomedical, biomaterial, and nanotechnological applications.14 
Amyloid nanofibrils have been successfully employed as a 
fundamental component in biomembranes,15 functional 
nanodevices,16, 17 hydrogels for cell culture and drug delivery,18, 19 
biosensors,20 functional materials with high biocompatibility and 
unique bio-recognition ability,21, 22 and energy conversion 
materials.23 All the above functions and applications of amyloid 
fibrils arise due to their unique structural features, enabling them to 
serve in an extremely vast context of fundamental and applied 
sciences, spanning from biology to materials science and 
nanotechnology.  
 At the atomistic length-scale the structural features of amyloid 
fibrils are remarkably similar,24, 25 with amino acids arranged into -
strands (separated by   4 Å) running orthogonal to the fibril axis 
and closely packed into -sheets running parallel to the fibril axis 
(typical intersheet distance  10-12 Å). In sharp contrast, the 
mesoscopic structure of amyloid fibrils shows a remarkable 
diversity, with a multitude of shapes and topologies, depending on 
the specific aggregation pathways followed.26, 27 To date, 
nanoparticles, nanofibrils, nanotubes, ribbons, nanosheets, and 3D 
scaffolds or multilayers represent just  some of the amyloid 
morphologies observed.28-31 A wide spectrum of available 
morphologies and free energies, high surface-to-volume ratio, high 
density of hydrogen bonds and the presence of biocompatible 
amino acids on their surfaces gives amyloid fibrils a remarkable 
range of nanomechanical properties and applications across many 
scientific fields.32,33 
 In this review, we will comprehensively analyse the relationship 
between the molecular mechanisms of assembly into amyloid fibrils, 
the resulting amyloid structure and polymorphism, and the ensuing 
physical properties. We will then discuss how the structure and 
physical properties of amyloids can be harnessed to provide 
applications as advanced materials and in nanotechnology. In Part 2 
we discuss the self-assembly and aggregation mechanisms of 
amyloids from unfolded proteins (e.g. α-synuclein), folded globular 
proteins (e.g. β-lactoglobulin) and peptides (e.g. Amyloid , Aβ). In 
Part 3 we review the main structural traits of amyloids from the 
atomic to mesoscopic length scale. In parts 4 and 5 we discuss the 
functionality of natural and artificial amyloid materials, and present 
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current biomedical, material, and nanotechnological applications of 
amyloid-based hybrid materials. We conclude by highlighting the 
current challenges and future perspectives of amyloid based 
materials and discuss emerging fields in which amyloid fibrils are 
ideal candidates to contribute to their development. It is expected 
that this comprehensive review will forge new directions for the 
design, synthesis, and wider applications of protein and peptide 
amyloid-based biological and functional materials. 
  
2. Self-assembly and aggregation mechanisms of 
amyloids 
The formation of amyloids can be achieved with either native 
folded proteins, which often have to undergo activation 
reactions such as unfolding and hydrolysis before aggregating, 
or unfolded proteins and peptides, which under a broad range 
of conditions exhibit 1D growth after a fast nucleation step. In 
this part, we would like to introduce key information on the 
self-assembly and aggregation mechanisms of peptides and 
proteins, which include a series of microscopic events such as 
protein unfolding, hydrolysis and aggregation. We describe the 
application of chemical kinetic studies to identify different 
microscopic mechanisms and we will discuss the connections 
between aggregation mechanisms and the length distribution 
of the aggregate population, which is a key property defining 
the function of the final amyloid product. 
 
2.1 Amyloidogenic proteins and peptides 
2.1.1 Protein folding and unfolding 
The formation of well-folded protein structures is central to the 
function of every living cell.34 Based on the information coded by 
DNA molecules and transcribed into messenger RNA, the 
ribosome synthesizes polypeptide chains of specific amino acid 
sequence that undergo internal organization to form distinct 
conformational arrangements. The spontaneous arrangement 
of the amino acid chain based on the physicochemical 
properties of its constituents is denoted as "protein folding".35 
The correct organization of the polypeptide chain into well-
folded three-dimensional arrangements allows the proper 
activity of proteins, including enzymatic activity, storage, 
transport, sensing, signalling and structural functions. The 
folding of proteins into the distinct thermodynamically 
favourable conformations is achieved through folding 
pathways that hierarchically direct the protein into the lowest 
energy thermodynamic state. Several canonical secondary 
structures, such as alpha-helix and beta-sheet, constitute the 
tertiary folding, a much more complex energy-minimized 
molecular organization. As will be further discussed, this 
dogma is currently challenged as the amyloid state of proteins 
and polypeptides may actually represent the true energetic 
minimum of protein assemblies. 
 Even though correct protein folding is required for their 
biological function, under certain conditions proteins can 
undergo an unfolding process losing their tertiary as well as 
secondary structure.36 The unfolding can be induced 
physically, especially by temperature changes (mostly heating 
and in some cases cooling), as well as by hydrostatic pressure, 
or chemically, by the addition of chaotropic agents (such as 
urea, guanidinium chloride, magnesium chloride, alcohols and 
detergents) that are able to disrupt the hydrogen bonding 
network between water molecules.  
 Protein unfolding can be either reversible or irreversible, 
depending on potential irregular interactions of the unfolded 
protein either within the same polypeptide chain 
(intramolecular interactions) or with neighbouring molecules 
(intermolecular interactions). The association of exposed 
hydrophobic surfaces is the main driving force of 
intermolecular interactions. Instead of a normal folding 
process in which the hydrophobic parts of a protein are buried 
in its core, many of these parts are held together by non-
covalent interactions. In the case of intermolecular 
interactions, the molecular assemblies can form ordered 
assemblies such as crystals or amyloid fibrils.37 
 
2.1.2 Unfolded proteins 
Unlike the more common case of folded proteins, many 
intrinsically unfolded proteins exist in a natively unfolded 
state, either for the entire molecule or at specific regions of 
the peptide chain.38-40 In such a case, hydrophobic parts of the 
proteins are exposed without any external unfolding reaction. 
Solution methods including nuclear magnetic resonance (NMR) 
and circular dichroism (CD) have allowed the determination of 
the unfolded state of proteins. The use of temperature-
controlled experiments allows the melting temperature to be 
determined. Indeed, in some cases proteins were found to be 
unfolded at physiological temperature (37 oC) but completely 
folded at a low temperature (e.g., 4 oC).41, 42 
 The basis for the existence of proteins in an unfolded state 
might have a clear physiological significance. One of the roles 
of protein unfolding is to control the physiological stability of 
such proteins. The fact that unfolded proteins expose 
hydrophobic patches, that are otherwise buried within the 
core of the protein, results in their identification as damaged 
proteins, leading to their degradation by the protein quality 
control machinery.43 The existence of proteins in this state 
allows the modulation of their half-life. In extreme cases, some 
proteins molecules could be degraded in a few minutes. This 
property is useful for two-component systems, such as 
bacterial toxin-antitoxin systems, in which the instability of 
one component is critical for the physiological control of the 
system.44 
 Protein unfolding plays a critical role in at least three 
biological processes such as protein translocation, protein 
degradation, and passive elasticity of striated muscle,45 in 
which the unfolding is thought to be induced by the cellular 
machinery pulling the polypeptide chain to better disentangle 
the native domains. For the amyloid fibrils formed by globular 
proteins, the unfolding is a necessary step to change the 
conformation of the protein from a minimum to another 
minimum in the protein folding energy landscape.46 
 
2.1.3. Misfolded proteins 
ARTICLE Journal Name 
4 | J. Name., 2013, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
 
 
As mentioned above, proteins can exist in an aggregated 
amyloid organization which was first associated with human 
diseases, including Alzheimer's disease (AD), Parkinson's 
disease and Type II diabetes.47 The intermolecular interaction 
between unfolded or partially unfolded proteins can lead to 
the formation of supramolecular -sheet structures 
constituted of more than one protein molecule. This could be 
considered an abnormal organization in which a handful of 
protein or polypeptide molecules join together to form 
ordered assemblies. 
 Amyloids were already identified more than a century ago 
in association with disease. In 1901, Dr. Eugene L. Opie, an 
American physician, had identified the formation of deposits in 
the pancreas of Type II diabetes patients.48 A few years later, 
in 1906, the deposition of biomaterial in the brain of a 
demented patient post mortem was found by Aloysius "Alois" 
Alzheimer in Germany.49 The deposits were denoted amyloids 
(starch-like) due to their positive staining by iodine as 
carbohydrate deposits. Only decades later, these aggregative 
forms were found to be made of proteins. With the 
advancement of electron microscopy in the 1950s, it was 
discovered that these protein assemblies have a typical 
nanoscale order. This regularity at the nanoscale underlies 
some of the properties that were later utilized for various 
technological applications, as described in this review. 
 The structure of amyloids regardless of their source is a 
very typical one comprising elongated supramolecular 
structures with a diameter of 7-10 nm. Amyloids have a 
predominantly -sheet secondary structure as determined by 
X-ray fiber diffraction (XRFD) and infrared or CD spectroscopy. 
Interestingly, both parallel and anti-parallel -sheet structures 
were observed within amyloid fibrils of different sources in 
spite of the very uniform ultrastructure. Amyloid fibrils were 
also found to bind to specific dyes. Beyond their ability to be 
stained with iodine, later on other amyloid specific dyes were 
identified, including Thioflavin T (ThT) and Congo red.50, 51 The 
use of Congo red is especially interesting due to the typical 
birefringence that is observed upon the staining of the amyloid 
fibrils when placed between cross-polarizers. It was suggested 
that proteins of unrelated origin could form remarkably similar 
structures in disease state. The hypothesis was that the 
formation of such structures plays a role in the damage to 
various organs and tissues observed in these diseases. Indeed 
this "amyloid hypothesis" was supported by the observation of 
notable toxicity of the amyloids or their earlier soluble 
intermediates. 
 A very important extension of the "amyloid hypothesis" 
was provided by Dobson and co-workers who realized that 
non-disease related proteins could also form typical amyloid 
fibrils with all the common structural and biophysical 
characteristics of disease-associated amyloid assemblies.52 It 
was thus suggested that the amyloid structure may actually 
reflect a generic minimal energy organization of polypeptide 
chains and that the structure of folded proteins is essentially a 
meta-stable kinetically trapped state, suggesting that most or 
all proteins would reach the favorable amyloidal organization 
at infinite time.53 This hypothetical notion was later supported 
empirically, as it was found that most cellular proteins are at 
the verge of aggregation ("life at the edge" phenomenon) and 
that the proteostasis of the biological system requires an 
advanced cellular machinery that can keep the proteins and 
polypeptides in a soluble state.54 
 
2.1.4. Peptide-based amyloids 
The formation of amyloid fibrils has also been identified in 
various functional peptides, including the islet amyloid 
polypeptide (37 amino acids), Amyloid  (40-42 amino acids), 
and human calcitonin (31 amino acids), all associated with 
human disease. The aggregated form of the islet amyloid 
peptide is found in the pancreas of Type II diabetes patients,55 
aggregated forms of A are found in the brain of Alzheimer's 
disease patients and similar structures made of calcitonin are 
found in the thyroid of patients with thyroid carcinoma, all 
identified using electron microscopy (EM). Furthermore, the 
peptide amyloids were found to share all other biophysical 
properties of protein amyloids, including the spectroscopic 
features, XRFD patterns and the staining with specific dyes. 
 As noted above, the formation of amyloid fibrils was 
initially identified in naturally occurring proteins and 
polypeptides. A reductionist approach has since been applied 
to identify the minimal peptide fragments that can form 
amyloid fibrils. Tenidis and co-workers were able to identify 
hexapeptide fragments of the islet amyloid polypeptide that 
form amyloid fibrils.56 Later studies identified the ability of a 
pentapeptide fragment of calcitonin, as well as heptapeptide 
fragments of A, to form such ordered assemblies.57 
 
2.1.5. Peptide nanostructures and non-protein amyloids 
Further reductionist approaches were used in order to identify 
even shorter amyloid-forming peptide motifs. It was found 
that the dipeptides diphenylalanine (FF) can form amyloid-
related assemblies. The diphenylalanine motif is at the center 
of the A polypeptide associated with Alzheimer's disease. As 
noted above, it was demonstrated that a heptapeptide 
fragment of A, KLVFFAE (Lys-Leu-Val-Phe-Phe-Ala-Glu) could 
form fibrillar assemblies, and two pentapeptide fragments, 
KLVFF and LVFFA, are inhibitors of amyloid formation by the 
full-length protein.58 It was found that the nanostructures 
made by FF shares many functional properties with amyloid 
assemblies,59, 60 including the intrinsic luminescence 
properties, binding of amyloid-specific dyes, mechanical 
rigidity and the production of reactive oxygen species. This 
suggests that the FF nanostructures indeed represent a highly 
simplified model that reflects the structural, biophysical and 
biochemical properties of amyloid structures.28, 61 
 Later studies identified the ability of various short peptides 
to form ordered assemblies. Frederix and co-workers screened 
over 8,000 naturally occurring tripeptides for the formation of 
supramolecular entities using molecular dynamics 
simulations.62 The most aggregation prone peptide screened 
peptide was PFF (Pro-Phe-Phe), and many other highly 
aggregating peptides contained the FF motif, and to a lower 
extent other diaromatic motifs (including FW, WF, FY and 
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WW). This comprehensive non-biased analysis of all peptides is 
consistent with the observation of the high occurrence of 
aromatic amino acids in short peptides that can form typical 
amyloid fibrils. 
 In order to identify the minimal requirement for amyloid 
formation, amino acids were also tested for their ability to self-
associate. Very surprisingly, it was found that phenylalanine 
could form amyloid fibrils with all the characteristics of protein 
fibrils, including nanoscale fibrillar morphology, binding of ThT 
and Congo Red and notable cytotoxicity.63 X-ray 
crystallography suggested the formation of -sheet like 
structures by this amino acid. Similar to protein amyloids, the 
phenylalanine amyloids were also found to bind to 
phospholipid membranes. Later on, it was found that other 
amino acids (including Trp, Tyr, and Cys), as well as nucleotides 
and other metabolites, could also form typical amyloid-like 
structures.64, 65 The formed assemblies reveal many 
ultrastructural similarities among themselves and to protein 
and peptide amyloids. It was therefore suggested that the 
amyloid hypothesis could be even further extended to include 
nonproteinaceous building blocks. 
 The simple synthesis, chemical diversity, small size and low 
cost make very short motifs, including tripeptides, dipeptides 
and single amino acids, ideal building blocks for various 
applications in nanoscience and nanotechnology.66, 67 
Moreover, the mechanical, optical, electric and piezoelectric 
properties of some self-assembled structures should allow 
their use as alternatives to inorganic components in electronic, 
electro-optic and electromechanical systems. The bottom-up 
assembly of complex nanostructures from these simple 
building blocks allows the utilization of fabrication techniques 
that were previously used in surface modification applications, 
including physical vapor deposition, printing using inkjet 
technology and unidirectional axial growth by controlled 
evaporation of volatile solvents. 
  
2.2 Factors controlling amyloid growth and kinetics 
2.2.1 Solution property-mediated amyloid formation 
2.2.1.1 PH-mediated amyloids 
The growth of amyloid fibrils is highly sensitive to solution 
conditions including pH, the presence of salts or denaturing 
agents etc. Very careful preparation protocols have to be 
followed in studying fibrillization of Aβ42, for example starting 
from a well-defined state of unaggregated peptide (achieved 
by initial dissolution in a hydrophobic solvent) and then 
carefully controlling the addition of water or buffer to a dried 
film.68 
 Typically, amyloid fibril formation by proteins is induced by 
reduction of pH. The aggregation of short peptides will depend 
on the pI of the peptide or the pKa of its constituent residues 
and its relationship to the solution pH. It has been suggested 
that fibril formation is favoured when the net charge of the 
peptide is not too large (in the range -1 to +1).69 
  
 
Fig. 1 Tapping mode AFM height images showing the morphology of 
C16-KTTKS at pH values (a) pH 2, (b) pH 3, (c) pH 4, (d) pH 7. Reprinted 
with permission from Ref. 76. Copyright 2013, Royal Society of 
Chemistry. 
 A study of amylin peptide fibrillization indicates the 
presence of two ionisable residues – the α-amino group at the 
N terminus and His18.70 The pKa values of the former unit in 
the amylin peptide is found to be similar to the random coil 
value (pKa = 8) however the His18 residue has pKa = 5.0, 
significantly lower than the random coil value pKa = 6.5. This is 
ascribed to the local influence of hydrophobic residues. His18 
is found to act as an electrostatic switch hindering fibrillization 
in its charged state. An apparent pKa = 4.0 for an amylin 
fragment peptide, NAc-SNNFGAILSS-NH2, which contains no 
titratable groups, is instead ascribed to the pH-induced 
ionization of the amyloid-sensitive dye, ThT.  
 In another example, the aggregation of the Amyloid β 
peptide Aβ1-42 was studied as a function of pH.71 This was 
investigated experimentally and the analysis was facilitated by 
molecular mechanics modelling of the fragment peptide Aβ17-
42 which revealed favourable electrostatic interactions 
between Asp23 and Lys28 (i.e. salt bridge formation) above 
the pI of the peptide. The aggregation of the Aβ1-42 peptide 
itself was analysed at lower pH. At pH > 9.5, aggregation was 
not observed because Lys28 was uncharged.71 
 The self-assembly of another type of amyloid-forming 
building block, the so-called peptide amiphiphiles (PAs), can 
also be mediated by the solution property. PAs are designed 
amyloidogenic peptides modified by the attachment of 
hydrophobic lipid tails,72 which then show combined 
surfactant-like properties and self-assembly ability.73 The pH 
value has a pronounced effect on the self-assembly of PAs. For 
example, the Stupp group has demonstrated that the PAs 
containing acidic amino acids could be triggered to self-
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assemble into nanofibrils at acidic pH74 or with the use of divalent 
cations.75 
 In another case, Dehsorkhi et al. found that a PAs 
containing the pentapeptide KTTKS sequence, i.e. containing 
two cationic lysine residues, could be assisted to form 
adjustable nanostructures ranging from spherical micelles to 
tape-like and twisted structures by simply adjusting the pH of 
the solution at 2, 3, 4, and 7, respectively.76 Atomic force 
microscopy (AFM) was used to image the morphology at selected 
pH values. It can be seen from Fig. 1 that fibrils, tapes or spherical 
micelles form depending on the pH (the net charge is approximately 
+1 at pH 7 and +2 at low pH). Small-angle x-ray scattering (SAXS) 
confirmed these morphology transitions and CD indicated a 
transition from β-sheet conformation in fibrils and tapes to 
disordered conformation at pH 2 for the spherical micelles. 
 
2.2.1.2 Ionic strength-mediated amyloids 
 Along with the pH dependence of amyloid formation, we also 
highlight a few pertinent examples, in which the ionic strength of 
solution as well shows close effects on the formation of amyloids. 
 Hoyer et al. investigated, together with the effects of pH, the 
role of salt concentration on the in vitro aggregation of α-synuclein, 
and observed morphologies of different aggregates formed by 
α-synuclein at varying pH values and in the presence and 
absence of salts (NaCl and MgCl2).77 Their results indicated that 
the morphology of α-synuclein aggregates is highly sensitive to 
the solutions conditions (both pH value and ionic strength). In 
another case, Raman et al. investigated the effect of salts such 
as NaCl, NaI, NaClO4, and Na2SO4 on the formation of β2-
microglobulin amyloid.78 The presence of salts increased the 
hydrophobicity of proteins, and the anion interaction caused an 
interplay between electrostatic and hydrophobic interactions 
during amyloid formation. The particular role of SO42- ions was 
identified, and this was suggested to be important in terms of the 
role of glycosaminoglycans and proteoglycans in amyloidogenesis. 
The critical aggregation concentration of β-lactoglobulin also 
depends on ionic strength, and below this concentration, mainly 
“dead-end” species are formed that consist of irreversibly 
denatured protein.79 The morphology of the fibrils also changes and 
shorter and more flexible fibrils are formed at higher ionic strength. 
 The formation of peptide amyloids could also be affected 
by ionic strength. For example, Marek et al. investigated the 
ionic strength effects on the formation of islet amyloid 
polypeptide (IAPP) fibrils.80 They suggested that the kinetics of 
IAPP amyloid formation is strongly dependent on the ionic 
strength in the range of 20-600 mM at pH 8.0. Recently, 
Abelein and co-workers characterized the explicit effect of 
ionic strength on the microscopic aggregation rates of Aβ40,81 
and found that the physiological ionic strength could 
accelerate the aggregation kinetics of Aβ40 by promoting the 
surface-catalyzed secondary nucleation reactions. Their results 
indicated the salts could decrease the free-energy barrier for 
Aβ40 folding to a mature stable state, favoring the formation of 
mature fibrils. 
 A recent model, based on DLVO-type colloid theory, 
accounts for the stability of amyloid fibril dispersions and 
allows for the influence of ionic strength, salt concentration (as 
well as the presence of organic reagents).82 The theory can be 
used to calculate quantities (fibril hydrodynamic radius and 
Fuchs stability ratio, which describes the energy barrier 
between two interacting fibrils) which were compared to 
experimental data for a model amphiphilic peptide (RADA 16-
I).82  
 
2.2.2 Temperature-mediated fibrillation 
Heating (with or without pH adjustment to acidic conditions) is 
another common method of inducing amyloid formation with 
proteins and peptides.25 Again, there are too many studies 
involving heat treatment to review them all and space permits 
only selected examples to be discussed herein. At sufficiently 
high concentration, the fibrillization of peptides is 
accompanied by gelation. For example, β-lactoglobulin forms 
fibrillar gels on heating at low pH values. Particulate gels are 
formed at higher pH values, close to the isoelectric point 
where the protein has a low net charge.83, 84 Cold denaturation 
is generally a milder form than hot denaturation and leads 
only to partial unfolding of proteins85 and so rarely, amyloid 
formation is reported under these conditions. However, cold 
can be used to dissociate amyloid fibrils, as discussed below. 
 Peptide amphiphiles (PAs) can show thermal transitions 
mediated by lipid chain melting behaviour as well as changes 
in the hydrogen bonding of amino acid residues, and 
temperature-dependent changes in solubility.  In one example, 
conjugates of C23 or C25 alkyl chains (both containing one 
diacetylene unit) and the bio-derived GANPNAAG peptide 
sequence were shown to have very different disassembly 
transition temperatures on heating, and distinct 
thermosreversibility properties.86 The longer chain PA 
reassembled on cooling, the shorter one did not.86 The same 
PA C16-KTTKS discussed in the previous section also exhibits 
interesting temperature-mediated fibrillization below 30 oC 
(depending on concentration), which may be associated with 
the palmitoyl chain melting temperature.87 At low 
temperature, this compound (Tradename Matrixyl) forms 
extended tape-like fibrils, but at high temperature small 
spherical micelles are observed.87 The thermoresponsiveness 
of other lipopeptides and peptides, for example elastin-like 
peptides which undergo LCST (lower critical solution 
temperature) behaviour, has been reviewed elsewhere.88 
 The formation of amyloid fibrils by the egg white protein 
ovalbumin occurs at high temperature (90 oC) and low pH, and 
the fibril morphology has been examined with or without 
NaCl.89 Two types of aggregate were observed – thin flexible 
wormlike fibrils or thicker periodically twisted ribbons. 
Differences in β-sheet content between the two were studied 
by CD, WAXS and Fourier transform infrared spectroscopy 
(FTIR) (the latter aggregate lacks amyloid characteristics). The 
stiffness of the two types of fibril also differs, as quantified by 
peak force-quantitative nanomechanical AFM.89 
 In another example, the fibrillization and defibrillization 
(‘depolymerization’) of β2-microglobulin was followed by 
detailed Thioflavin T fluorescence measurements.90 Incubation 
at 99 oC for 10 min was found to lead to complete dissociation 
of fibrils into monomers. This occurred via both fibril breakage 
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and dissociation of monomers from fibril ends. 
Repolymerization experiments revealed that the number of 
extendable fibril ends increased significantly upon incubation 
at elevated temperatures. Stabilization of fibrils using a 
number of additives (salts or surfactant) was examined and it 
was found that the anionic surfactant SDS (sodium dodecyl 
sulfate) can prevent fibril dissociation up to 99 oC.90 
 
Fig. 2 Schematic of defibrillization of -synuclein upon either cold or 
hot denaturing. Reprinted with permission from Ref. 91. Copyright 
2014, Wiley-VCH Verlag GmbH &Co.. 
 Whilst amyloid fibrils of many peptides such as β2-
microglobulin and Aβ1-40 or Aβ1-42 undergo heat-induced 
breakup, cold denaturation (dissociation into monomers) was 
additionally observed for α-synuclein (Fig. 2).91 CD 
spectroscopy was used to monitor the loss of β-sheet structure 
on cooling (to 0 oC), and the temperature dependence was 
analysed, along with additional isothermal titration 
calorimetric (ITC) measurements, to provide thermodynamic 
information. This suggests that cold denaturation results from 
the burial of charged residues in the core of α-synuclein fibrils, 
opposite to the case of protein folding.91 The dissociation of 
amyloid fibrils under cold conditions is exemplified by a study 
on α-synuclein in supercooled water at -15 oC.86 
 The denaturation of insulin under extreme temperature 
conditions up to 140 oC was probed via CD and ThT 
fluorescence experiments.92 Amyloid structure was gradually 
replaced with random coil structure above 80 oC until no 
amyloid structure was detected at 140 oC.  Fibrillization was 
observed when the sample was cooled down to 100 oC and 
incubated showing that even exposure to very high 
temperature, which favours full unfolding, does not lead to 
completely irreversible denaturing.92 
 
2.2.3 Organic reagent-induced fibrillation 
Protein denaturing agents such urea, salts or guanidinium 
hydrochloride or surfactants (e.g. SDS) may cause amyloid 
fibril formation. For example, many studies on amyloid fibril 
formation by the prion protein PrP have involved chemical 
denaturants that promote non-native conformational states.93 
Alcohol co-solvents generally lead to an increase in β-sheet 
structure associated with fibril formation of peptides and 
proteins. On the other hand, high concentrations of 
hexafluoroisopropanol (HFIP) or 2,2,2-trifluoroethanol (TFE) 
inhibit aggregation (and are widely used to disperse peptides 
and proteins in an unaggregated form). Acetonitrile is also 
reported to have an effect in inhibiting fibrillization.7 
 In a further example, the formation of fibrils (so-called 
protein nanofibers) by the extracellular matrix (ECM) adhesion 
protein fibronectin was observed after incubation at 37 oC in 
water/ethanol mixtures.94 The fibrils were used as scaffolds to 
deposit N-hydroxysulfosuccinimide (NHS) modified CdSe–ZnS 
core–shell quantum dots (QDs) with potential applications as 
biophotonic nanohybrid materials. Fibrinogen also forms fibrils 
by incubation at pH 2, and these were used as templates for 
biomineralization.95 
 
2.2.4 Metal ion-induced fibrillation 
Metal ions are associated with amyloid deposits in several 
neurodegenerative disorders including Alzheimer’s, Parkinsons 
and prion diseases. Metal ion coordination (through residues 
such as histidine) may cause inter-peptide crosslinking (Fig. 3 
shows possible structures) and in turn influence 
oligomerization and fibrillization. In Parkinson’s disease, 
elevated levels of copper and iron ions are found in the 
cerebrospinal fluid and Lewy bodies (which are intracellular 
inclusion bodies containing β-sheet rich aggregates of α-
synuclein).96 An early characteristic of prion disease is metal 
imbalance and Cu2+ has been found in scrapie isolates and 
confers prion strain type.96 Furthermore, copper ions, found in 
trace quantities in the bloodstream, are known to bind to PrP 
in vivo and in vitro and to influence PrP levels in the brain. 
Aggregation of Aβ in Alzheimer’s disease may also be 
promoted by metal ions.97-101 Metal ions (e.g. Cu2+, Fe3+, Zn2+, 
Al3+…) were found to be co-localized at abnormally high 
concentration with senile plaques in AD brains.102-106 
Furthermore, Aβ rapidly aggregates in the presence of 
physiological concentrations of Zn2+ at pH 7.4.107-109 In addition, 
metal ion-mediated amyloid formation is thought to be 
associated with inflammation in AD patients. For example, 
Cu2+-induced aggregation was enhanced at mildly acidic pH 
values associated with inflammation.109 The apparent 
interdependence of metal ions and amyloid assembly in AD 
opens up potential therapeutic targets. For instance, 
treatment with metal ion chelators can reduce the deposition 
of Aβ in brains.110-113 The majority of studies to date have 
focused on metal ions ability to enhance Aβ fibrillation (e.g. 
Cu2+, Zn2+ Al3+ and Fe3+).114 However, some studies have 
proposed that under certain conditions copper,111, 115, 116 and 
zinc111, 115 (but not iron111) ions are non-fibrillogenic. It should 
be noted however that amorphous and/or oligomeric 
aggregates may still be promoted through increased 
intramolecular bridging. This was exemplified by a study of 
different fragments of Aβ peptides, some of which promote 
fibrillization whilst others reduce fibril formation.116 Apart 
from Aβ, di- and tri-valent metal ions have been shown to 
cause significant increases in the rate of fibril formation of α-
synuclein and there appears to be a correlation to ion charge 
density.117 The binding between protein and metal ions occurs via 
metal-ligand supramolecular interactions, which has been studied 
in detail for model metal ions by Bolisetty et al. both by molecular 
dynamic simulations and binding isotherms.118 
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Fig. 3 Proposed modes of metal ion binding involved in the 
aggregation of the three proteins or peptides indicated. Reprinted 
with permission from Ref. 96. Copyright 2012, Elsevier Ltd. 
 The subject of peptide self-assembly triggered by metal 
ions has been reviewed in depth.119 Many artificial ligands for 
metal ions have been incorporated into peptide-based 
molecules, and in addition the influence of metal ions on 
peptides incorporating natural ion-binding residues (histidine, 
cysteine, tryptophan or glutamic acid) has been examined. 
Self-assembly into different structures including α-helix based 
structures, β-turns etc has been reviewed,119 but this is outside 
the scope of the current review. 
   
2.2.5 Biopolymer-induced formation 
Proteoglycans are an essential component of the ECM and 
they have important effects on amyloid aggregation in vivo 
and these have been investigated in vitro. Glycosaminoglycans 
(GAGs) or proteoglycans are thought to be associated with AD 
since sulfated GAGs such as heparin or chondroitin sulfate are 
present in neuritic plaques, neurofibrillary tangles and vascular 
amyloid deposits.113, 120-122 Binding of some sulfated GAGs can 
prevent the proteolytic degradation of fibrillar Aβ. Sulfated 
GAGs can interact with histidine residues on peptides such as 
Aβ. Interestingly, sulfated GAGs can promote fibril formation 
due to a charge templating effect.123 It has been reported that 
the sulfate spacing in heparin and several other GAGs is ideal 
for β-sheet formation (with associated 4.8 Å strand spacing), 
but this is not the case for some other polysaccharides.123 In 
parallel studies, it has been reported that heparin or heparin 
sulfate can accelerate the fibrillization of Aβ in vitro,121 
probably due to electrostatic binding to a specific domain in 
the Aβ11-28 region.124 The influence of uncharged 
polysaccharides on fibril formation has been less studied, 
although one study suggests that glycogen can promote β-
sheet formation of the prion protein.125 
 In a few cases, the inhibition of amyloid fibrillization by 
polysaccharides has been reported, for instance κ-carrageenan 
forms a complex with positively charged β-lactoglobulin which 
partly hindered high temperature fibril formation.126 
Uncomplexed β-lactoglobulin still formed fibrils, but protein-
carrageenan complexes did not. Chitosan and 
poly(vinylsulfate) have an inhibitory effect on Aβ1-42 
fibrillization.123 The influence of proteoglycans on amyloid 
fibrillization is reviewed elsewhere.7, 114 
 Linse’s group has investigated the effects of polyamino 
acids and polyelectrolytes on Aβ fibrillization.127 They 
investigated the kinetics of Aβ1-42 aggregation using ThT 
fluorescence measurements and observed a concentration 
dependent accelerating effect on the aggregation process from 
all positively charged polymers examined (polyglutamic acid 
and polyacrylic acid). In contrast, no effect was seen for the 
negative polymers polylysine or poly(ethylenimine) or 
poly(diallyldimethyl ammonium chloride) or the neutral 
polymers polythreonine.127 
 The interaction between nucleic acids and amyloid fibrils 
has been investigated by several groups. DNA is known to be a 
powerful promotor of fibrillization due to electrostatic 
interactions with negatively charged residues on the DNA. 
Complexation of DNA with two arginine-containing molecules - 
one bola-amphiphile and one PA, has been examined.128 Both 
of these peptide-based compounds self-assemble into layered 
β-sheet structures with incorporated DNA, the structural 
integrity of the DNA being maintained. 
 In another example, it was shown that DNA origami 
nanotubes can sheathe transthyretin fragment amyloid fibrils 
formed within them.129 A DNA origami construct was used to 
form 20-helix DNA nanotubes with sufficient space for the 
fibrils inside. 
 
2.2.6 Nanoparticle induced/inhibited amyloid fibrillation 
Nanoparticles can significantly influence amyloid formation 
because they may catalyse fibril formation due to increased 
local protein concentration or they may inhibit aggregation 
when there is strong binding or a large particle/protein 
interaction surface area.130 In the context of high local amyloid 
concentration, nanoparticle/amyloid hybrids are have been 
proposed as model systems to understand amyloid formation 
under crowded conditions relevant to those observed in 
vivo.131 The effects of nanoparticles on amyloid formation may 
also be related to aspects of protein adsorption on 
nanoparticles in the blood stream, with relevance to 
nanoparticle toxicity.132 The ability of a nanoparticle to 
influence amyloid aggregation is dependent on the stability of 
the protein and its intrinsic aggregation rate.130 Amyloid 
fibrillization in the presence of nanoparticles with varying 
hydrophobicity and other surface chemistries has been 
examined. Polymeric nanoparticles can either increase or 
decrease the fibrillization of amyloid proteins, depending on 
the nanoparticle hydrophobicity and the unfolding behaviour 
of the protein and the hydrogen bonding capacity of subunits 
within it.133 
 Polymeric nanoparticles (uncharged acrylamide-based 
copolymers) inhibit the fibrillization of Aβ1-40, an observation 
ascribed to the binding of Aβ (in monomeric or oligomeric 
form) to the nanoparticles.134 The binding mainly affects 
nucleation, and the lag time was found to be strongly 
influenced by the copolymer composition. The binding is due 
to a combination of hydrophobicity (controlled via copolymer 
composition) and hydrogen bonding between polar groups on 
the polymer and in Aβ.134 In the case of cationically (amide) 
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functionalized polystyrene nanoparticles, inhibition of 
fibrillization is observed for high particle surface area, whereas 
fibrillization is accelerated for low particle surface areas due to 
reduction of the lag phase.135 
 Inorganic nanoparticles can function as Aβ fibrillization 
inhibitors, although this was demonstrated with cytotoxic 
CdTe nanoparticles.136 On the other hand, it seems that TiO2 
nanoparticles can promote Aβ fibril formation by reducing the 
nucleation period,137 however, the precise mechanism is 
unclear. Polyoxometalates which comprise inorganic early 
transition metal clusters also inhibit the aggregation of Aβ.138 
Surprisingly, inorganic nanoparticles based on porous silica 
have been shown to penetrate the brains of fruit flies (D. 
melanogaster), without exhibiting neurotoxic effects and 
potentially enabling delivery across the blood-brain barrier 
(BBB).139 BBB permeability can be modeled using the parallel 
artificial membrane permeability assay, which measures 
passive diffusion of small molecule through an artificial lipid 
membrane.140, 141 
 There is growing evidence that metal nanoparticles may 
act as seeds for amyloid nucleation and growth,142 an 
observation which can be relevant for amyloid related 
neurodegenerative diseases in the light of the fact that 
nanoparticles may be able to pass through the BBB. For 
instance, nucleation of amyloid oligomers has been reported 
on gold nanorods,143 for a  model synthetic bacterial protein 
which was functionalized with a hexa-histidine tag for binding 
to the gold surface. Conformational changes in the bound 
protein were probed using surface-enhanced Raman 
spectroscopy (SERS) and the nucleation was ascribed to the 
formation of immobilized pre-amyloidogenic monomers.143 
Gold and silver nanoparticles have been shown to accelerate 
fibril growth of the NNFGAIL peptide from human islet amyloid 
polypeptide and the prion protein Sup35 peptide GNNQQNY in 
physiological aqueous solutions.144 Large-scale molecular 
dynamics simulations highlight the role of the structural 
reorganization of the peptide corona around gold 
nanoparticles as being the rate-limiting step in the aggregation 
process.145 
 Both metal ions and metal nanoparticles could promote 
the formation of amyloid fibrils, but the nature of their binding 
with proteins is different. Metal nanoparticles adhere with 
amyloids basically by electrostatic interactions and surface 
tension reduction, while metal ions bind to amyloids via 
supramolecular metal-ligand interactions.  
 
2.2.7. Interface- and mechanical force-mediated amyloid 
formation 
 It has been suggested that fibrillization kinetics can be 
influenced during mixing by mass transfer effects. In addition, 
mixing leads to shear forces, which can influence the growth of 
fibrils by perturbing the equilibrium between soluble protein 
molecules and proteins incorporated into fibrils, since fibrils 
can fragment and create new nuclei.146 The possibility to 
fragment fibrils by mechanical forces has been commonly 
exploited to produce monodisperse short amyloid fibrils by 
sonication of long filaments. For instance, Chatani et al. 
studied this process for β2-microglobulin.147 However, 
(ultra)sonication is not always required to produce low 
dispersity (in width) amyloid fibrils as exemplified by the 
protocol used by the Mezzenga group to prepare well defined 
β-lactoglobulin fibrils, which does not involve sonication.148  
 The influence of shear on the structure and mechanical 
properties of amyloid fibrils of this protein has been 
investigated using both controlled (steady shear in a Couette 
cell) or uncontrolled (stirring) shear flows. It has been 
observed that distinct morphologies (with different 
mechanical behaviour) can be obtained depending on the 
shear conditions.149 Couette shear induces amyloid fibril 
formation in β-lactoglobulin starting from spheroidal seed-like 
species.150 In contrast, bovine serum albumin undergoes 
irreversible unfolding (without amyloid formation) in Couette 
flow.151 The influence of mechanical stress (linear shaking) on 
the fibrillization kinetics and morphology of glucagon has been 
examined.152 Studies of this type highlight the need for great 
care in the interpretation and comparison of amyloid 
formation kinetic data. 
 Many amyloid-forming proteins and peptides have 
surfactant-like properties and are active at the air-water 
interface. This leads to the possibility to use amyloid fibrils as 
emulsifying agents.153, 154 For example, a designed β-sheet 
forming peptide containing alternating phenylalanine and 
charged residues was able to act as a water-oil emulsifier.153  
Fibrillization of α-synuclein is enhanced at the air-water 
interface compared to that at a solid-liquid interface because 
fibrils are selectively adsorbed at the air-water interface.155 
Fibril nucleation is observed even without the presence of 
seeds although fibril elongation is faster in bulk when seeds 
are added at sufficient concentration.155 A designed coiled-coil 
peptide forms α-helices at the air-water interface which can 
transform into β-sheets, either with intrinsic slow kinetics or 
stimulated by the addition of metal ions such as Zn2+.156 At the 
interface, increasing peptide conformation or parallel 
alignment (by compression) of the α-helical intermediates 
(which tends to pre-align β-strands), has the greatest effect on 
β-sheet aggregation. The metal ions actually hindered 
aggregation of this peptide in bulk but not at the interface.156 
 
Fig. 4 Formation of amyloid fibrils by α-synuclein. A solution was 
agitated in the presence of particles of hydrophobic PTFE, slightly 
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hydrophilic PMMA or chemically inert glass; experiments with air 
injected at the top of the cuvette were also performed. Inset: 
Proposed mechanism of the fibrillization. The aggregation of proteins 
into fibrils (at the rate constant kfib), caused by association of the 
protein hydrophobic NAC domains, is enhanced in the presence of 
hydrophobic PTFE interface. Reprinted with permission from Ref. 158. 
Copyright 2010, Nature Publishing Group. 
 The presence of hydrophobic interfaces can influence the 
fibrillization of amyloid-forming proteins. Pronchik et al. 
studied the fibrillization of α-synuclein using a standard 
fluorescence dye technique used to assay amyloid 
formation.157 The kinetics of fibrillization in dilute aqueous 
solutions of the protein were monitored as a function of 
incubation time, the samples being subjected to agitation in 
the presence of different types of particles of 1-2 mm in 
diameter (Fig. 4).158 The particles were made of borosilicate 
glass which is largely inert, polymethylmethacrylate (PMMA) 
which is slightly hydrophilic or polytetrafluoroethylene (PTFE) 
which is hydrophobic. Some samples were also agitated in the 
presence of controlled volumes of air (which is hydrophobic). 
The fibrillization kinetics were found to depend strongly on the 
number of PTFE particles, i.e. to the hydrophobic surface area. 
The inverse lag time also increased in a non-linear fashion with 
the number of PTFE particles. Further nucleation and growth 
of fibrils was induced by addition of PTFE particles to a sample 
containing fibrils that had already developed upon agitation in 
the presence of PTFE particles. An increase in dye fluorescence 
was observed in the presence of air, although fibrils were not 
observed using AFM. In the case of glass particles, no fibril 
formation was observed. Fibrillization was observed using 
PMMA particles, but to a much lower extent than with PTFE 
particles. As a further control, quiescent samples were 
examined and these showed no increase in ThT fluorescence in 
the absence of agitation. The fibrillization kinetics were 
proportional to the PTFE surface area, but not to the surface 
area of glass or PMMA. The contact angle of PTFE decreases 
dramatically in the presence of protein, showing that the 
protein coats the PTFE surface progressively reducing the 
amount of available catalytically active interface. Moreover, 
the fact that addition of more PTFE particles leads to re-
initiation of growth indicates that saturation of adsorption had 
not occurred since fibril-capable protein was still present in 
solution. Accelerated fibrillization was also observed in the 
presence of air, although the morphology of fibrils was 
different (globular aggregates were observed). These results 
clearly show the importance of hydrophobic interfaces in 
accelerating the fibrillization of the amyloid-forming protein α-
synuclein. These findings provide an important insight to the 
understanding of the issues of sample-to-sample 
reproducibility that plague in vitro studies of amyloid 
fibrillization. Variability in morphology resulting from mixing in 
the presence of hydrophobic interfaces may also be important 
since fibril polymorphism, resulting for instance from 
sonication, has a profound effect on toxicity.159  
 The effect of lipid membranes on amyloid aggregation has 
been examined for several peptides including Aβ and α-
synuclein.160, 161 The importance of lipid interactions with Aβ is 
highlighted by the fact that apolipoprotein E, ApoE, (especially 
the ε4 allele) a key genetic risk factor for AD, is involved in lipid 
metabolism.162, 163 Lipid membranes have a number of 
important roles in modulating amyloid fibrillization. These 
include: (partially) unfolding the peptide, increasing the local 
concentration of peptide bound to the membrane, orienting 
the bound protein in an aggregation-prone manner and 
variation of penetration depth into the membrane affecting 
the nucleation propensity.164 Lipid rafts are implicated in Aβ 
dimer and oligomer formation,165-167 and may provide 
platforms for selective deposition of different Aβ aggregates 
(this also depends on the ordering of the lipids within the 
membranes which may be different in the rafts168).169 Further 
information on the interaction of Aβ with membranes is 
available elsewhere.114 
 Lipid membranes are influenced by amyloid peptides and 
vice versa. Advanced fluorescence imaging techniques enabled 
membrane disruption caused by native and mutant forms of α-
synuclein to be examined.170 It has been shown that171 α-
synuclein partially inserts into the outer leaflet of the lipid 
bilayer172 and it was thought that this was due to interaction 
with anionic lipid membranes.171, 173 However, it has been 
demonstrated that the protein is able to remodel lipid 
membranes from vesicles to tubules, even when the lipid 
membrane has no net charge.171  
 The cross-interaction of IAPP and Aβ peptides at lipid 
membranes has also been investigated.174 Mixed fibrils are 
formed at the anionic lipid raft membranes.174 
 
2.3 Aggregation mechanisms and kinetics of proteins and peptides 
2.3.1 Aggregation mechanisms of unfolded and folded proteins 
In the previous sections we discussed the effect of several 
physicochemical parameters on the conversion of soluble 
monomeric peptides and proteins into insoluble amyloid fibrils. In 
most of these systems, the formation of amyloids is the 
consequence of an aggregation process under kinetic control. In this 
perspective, amyloid formation differs from other types of protein 
aggregation phenomena that are under thermodynamic control, 
such as protein oligomerization, precipitation and liquid-liquid 
phase separation. In the light of this observation, the kinetics and 
the mechanisms of amyloid formation play a key role in 
determining the properties and the functions of the final fibrillar 
products. Therefore, in order to design amyloid products with 
tailored functions, the understanding of the microscopic 
mechanisms underlying the aggregation process represents a 
crucial component.154  
 This task exhibits several challenges, since the formation of 
amyloids is the consequence of a complex aggregation network 
represented by several elementary reactions of nucleation and 
growth (Fig. 5a).175, 176 The formation of amyloids is triggered 
initially by primary nucleation processes, which generate the first 
nuclei from soluble monomers. These nuclei can be represented 
by a variety of different small soluble species, which can be 
defined with different terminologies depending on their size, 
structure and reactivity. In the context of this section we define 
generically this broad class of small assemblies as oligomers. 
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Some of these species are non-reactive and off-pathway with 
respect to the transition into amyloids and accumulate in the 
system, while other oligomers are on-pathway and can further 
grow into protofibrils and eventually into mature filaments.177-179  
 In the vast majority of amyloid systems fibril growth occurs 
via elongation reactions, where a monomeric unit is incorporated 
at the end of an existing fibril via a diffusion motion over an 
energetic barrier.180 This process can in principle be reversible. 
However, the dissociation of monomers from fibrils is typically 
negligible, given the high thermodynamic stability of the fibrillar 
structure. In a very few cases, fibril growth can occur via fibril-
fibril aggregation, as observed for amphiphilic peptides exhibiting 
complementary defects at the fibril ends.181 
 In addition to primary nucleation reactions, secondary 
nucleation processes have been increasingly identified in the 
aggregation of several amyloidogenic peptides. Such secondary 
nucleation processes involve typically the fragmentation of fibrils 
induced by either thermal energy or mechanical forces.146, 182 
These breakage events multiply the number of fibrils and 
increase the concentration of reactive fibril ends which can 
recruit monomers and elongate. Another common secondary 
nucleation process, originally identified in seminal studies on 
sickle haemoglobin,183 involves the generation of new oligomers 
catalysed by the presence of the surfaces of existing fibrils.184-187  
Such surface-induced secondary process has been demonstrated 
to account for most of the production of toxic species during the 
aggregation of the peptide Aβ185 and, under certain conditions, 
also of α-synuclein.188 Importantly, these mechanisms of 
aggregation, commonly identified in vitro, are recently starting to 
find correlations also in in vivo studies performed using worms189 
and mice models190. 
 The generic aggregation mechanism described above applies 
to both unfolded and globular proteins forming amyloids. A key 
difference between these two classes of proteins, however, is 
related to the monomeric form responsible for initiating and 
propagating aggregation. Indeed, short peptides and largely 
unstructured proteins are typically prone to form amyloid fibrils 
without the requirement of major conformational changes.54, 191 
In contrast, the formation of amyloids from proteins that are 
largely folded follows typically a pre-aggregation event that 
triggers the conversion of the native form into an aberrant 
conformation that is more aggregation-prone. 
 One of the most common events is protein misfolding, i.e. 
the conformational change of the initially folded state into an 
unfolded or partially-folded intermediate.192-194 This is the case 
for instance for insulin,195-198 lysozyme,199, 200 β2-microglobulin,201, 
202 enzyme superoxide dismutase (SOD1),203 and light chain 
immunoglobulin,204 which have been observed to form fibrils 
under conditions that promote the formation of partially folded 
species. 
 Other reactions that can trigger the formation of amyloids 
from globular proteins involve the truncation of the protein205 or 
the hydrolysis of the original polypeptide sequence into smaller 
fragments. For instance, lysozyme206, 207 and β-lactoglobulin206, 
208, 209 have been shown to form amyloid fibrils under acidic 
conditions after the hydrolysis of the full-length protein into 
smaller peptides. In particular, two classes of peptides can be 
identified based on their reactivity: a series of peptides which 
converts over time into amyloids and a second sub-class which 
does not aggregate and remains soluble.208, 209 An analogous 
system is represented by the amyloidogenic peptides Aβ1-40 and 
Aβ1-42, which are generated from the enzymatic cleavage of the 
amyloid precursor protein (APP).114 The higher aggregation 
propensity of short peptides with respect to the precursor 
globular protein is not surprising, since steric constraints 
disfavour the thermodynamic stability of amyloid fibrils with 
respect to the soluble state for polypeptide sequences longer 
than 100 residues.54 Indeed, for large globular proteins such as 
immunoglobulins the formation of amorphous fractal-like 
aggregates rather than fibrils is typically more favoured.210-212 
 The formation of individual amyloid filaments can be 
followed by additional supramolecular events, leading to the 
generation of 2D and 3D amyloids. These additional processes 
include lateral fibril-fibril association206 as well as the formation 
of nematic phases213, 214 and gels154, 215. This rich phase behaviour 
opens a route to finely tune the morphology and the mechanical 
properties of supramolecular fibrillar hydrogels and other soft 
materials by carefully controlling the individual events underlying 
the aggregation process. This observation highlights once more 
the importance of identifying the aggregation mechanisms to 
allow rational design in structure-function studies of amyloid 
materials. 
 An attractive strategy to modulate the aggregation 
mechanisms in a tailored way consists of introducing into the 
system suitable reactive species. For instance, aggregation 
reactions can be seeded by adding pre-formed fibrils or other 
non-native species, which can trigger the aggregation of 
physiological monomers following prion-like mechanisms. As 
discussed previously, other important heterogeneous nucleation 
events involve the presence of air-water interfaces,155 
hydrophobic surfaces157, 216 and vesicles,160 which are particularly 
prone to trigger the formation of amyloid fibrils, although the 
exact mechanisms underlying these effects are only starting to be 
elucidated. 
 We conclude this paragraph by highlighting two emerging 
directions in amyloid mechanistic studies: a first activity is aimed 
at increasing our understanding of the microscopic steps 
underlying the generation of the oligomers.217 This topic is clearly 
relevant to understand the toxicity associated with the 
aggregation process in biological systems, and it is also crucial to 
clarify safety issues associated with the use of amyloid 
biomaterials for healthcare applications. A second important 
direction is the description of the behaviour of proteins at high 
concentrations, which underlies several biotechnological and 
biological applications. Indeed, under these conditions, the 
quaternary state of proteins is governed by a complex physics, 
since the increase of the protein concentration can both change 
the phase diagrams and accelerate the rate of nucleation and 
growth reactions by increasing the activities of the reagents. 
There is therefore the need to correlate the thermodynamic 
phase behaviour with the kinetic aspects of the aggregation 
processes. 
 
2.3.2 Identifying aggregation mechanisms from kinetic studies 
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In order to identify the microscopic aggregation mechanisms in a 
particular system, it would be convenient to fully characterize the 
large class of intermediate species populated during the 
aggregation process. However, several of these intermediate 
species are transient and present at low concentrations, and 
therefore challenging to characterize experimentally. Indeed, 
biophysical assays for structural studies are typically well suited 
to characterize only the initially soluble monomeric state and the 
final insoluble fibrillar aggregates. 
 To address this limitation, in analogy with other branches of 
chemistry and protein biophysics, chemical kinetics is emerging 
as a powerful tool to investigate amyloid aggregation 
mechanisms at the molecular level from the measurements of 
macroscopic rate laws.146, 193, 218 By recording the global 
aggregation profiles at different protein concentrations, the 
reaction orders can be extracted, and compared with integrated 
laws based on mathematical models describing different 
microscopic mechanisms.219 One of the greatest advantages of 
this method is the possibility to extract information on multiple 
microscopic events of nucleation and growth from a limited 
number of experimental macroscopic read-outs, which typically 
include the monomer conversion or the total amount of 
aggregates formed during time. 
 For instance, high-throughput assays have been well 
established to monitor the formation over time of the total fibril 
content. A conventional method is based on a ThT fluorescent 
assay,220, 221  which relies on the increase of the fluorescence 
yield of the dye upon binding to the characteristic β-sheet 
structure of the fibrils. The time evolution of the total fibril 
content typically exhibits a sigmoidal profile, where a lag-phase is 
followed by an exponential growth regime and eventually by a 
plateau related to the consumption of soluble monomer. It is 
important to note that the microscopic reactions described in the 
previous section are present during all the stages of the 
aggregation process, even at the early beginning of the reaction. 
Indeed, although it may be tempting to consider the lag-phase as 
a waiting time, this period represents the time required by the 
fibrils to reach a critical concentration that is detectable by the 
experimental assay.222, 223 
 The application of chemical kinetics in amyloids has been 
hampered for a long time by the complexity of the non-linear 
aggregation scheme described in the previous paragraph, which 
has challenged the derivation of analytical rate laws. Moreover, 
the high sensitivity of amyloids to several physicochemical factors 
complicates the establishment of robust kinetic assays, which 
often suffer from irreproducibility issues. Advances in theoretical 
analysis,146 and the development of optimized experimental 
protocols,224 however, have recently opened the possibility to 
apply the kinetic platform to several amyloidogenic systems, 
leading to the identification of the aggregation mechanisms 
under a broad range of conditions. 
 An attractive advantage of kinetic studies is the high 
sensitivity in detecting, also with high resolution, changes in the 
aggregation mechanisms that derive from the modulation of the 
reagent composition or of intrinsic and extrinsic factors.160, 185, 188, 
189, 225-227   
 Of particular interest is the analysis of the changes in the 
aggregation mechanisms in the presence of inhibitors of amyloid 
formation. This information is particularly important in the 
biomedical context of the search for drugs to fight against 
amyloid-related disorders, where a kinetic inhibition of the 
aggregation process can represent an effective strategy to avoid 
the onset and development of the associated disorders over a 
characteristic life span.114 It is becoming apparent, however, that 
this approach cannot be achieved simply by a generic inhibition 
of the aggregation process but requires a specific intervention 
aimed at targeting specific microscopic events that are most 
responsible for the formation of toxic species, in particular 
oligomers.228 In this context, the application of chemical kinetics 
is fundamental to identify the specific processes that are affected 
by the presence of different modulators.228, 229  
 
Fig. 5 a) Individual microscopic events underlying the aggregation 
mechanisms of amyloids; b) The identification of the aggregation 
mechanisms and the specific intervention on targeted microscopic 
reactions is fundamental for the rational design of tailored functions. This 
concept is illustrated here with the example of the peptide Aβ1-42, for 
which the generation of particularly active species can be modulated by 
inhibiting different microscopic steps. Reprinted with permission from 
Ref. 225. Copyright 2015 Nature Publishing Group. 
 A recent example of the importance of this activity has been 
demonstrated with the peptide Aβ1-42: the application of 
chemical kinetics and the understanding of the microscopic 
mechanisms underlying the aggregation process has opened the 
possibility to tune in a controlled way the generation of specific 
intermediates characterized by a particularly high level of toxicity, 
as shown in Fig. 5b.225 This platform allowed the identification of 
a biological molecule which can selectively supress the secondary 
nucleation reaction and therefore the generation of the 
oligomers.  By contrast, specific targeting of primary nucleation 
and elongation rate, although equally efficient in delaying the 
formation of the fibril amount (top panels) cannot deplete the 
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oligomer formation (bottom panels). This outcome would have 
not been achievable by means of experimental characterization 
only, and highlights the importance of theoretical mechanistic 
frameworks in structure-activity studies of amyloids. 
 It is envisioned that in the near future improvements in 
experimental assays to detect oligomers217, 230, 231 will enable 
researchers to perform kinetic studies specific to these species, 
thereby improving the understanding of the microscopic steps 
responsible for the formation of these important intermediates. 
 
2.3.3 Aggregation mechanisms and fibril length distribution 
In the previous paragraphs we discussed the importance of 
identifying aggregation mechanisms in amyloids and we 
described the use of chemical kinetics as one of the major tools 
to perform this operation. A particularly important aspect of 
these activities that deserves special attention in material 
sciences is the characterization of the time evolution of the fibril 
length distribution. Indeed, fibrils with different lengths are 
associated with drastically different mechanical properties and 
activities, including different toxicity in biological systems.232 
 From an experimental point of view, different techniques 
have been successfully applied to characterize the fibril length of 
amyloids. Single-molecule imaging techniques, including AFM,209, 
233-237 EM225 and super resolution fluorescence microscopy,238, 239 
provide a high level of resolution by analysis of a large number of 
individual filaments. Alternative bulk methods have also been 
recently developed based on the indirect evaluation of the fibril 
length from the measurement of physicochemical properties 
such as the rotational240 or translational diffusion coefficient241, 
242 or the sedimentation coefficient.243-247 
 In addition to the improvements in the experimental 
characterization, recent progress in the analytical treatment of 
kinetic models has allowed the derivation of compact 
expressions describing the dependence of the fibril length 
distribution on key kinetic parameters.248, 249 Experimental 
information on the full length distribution provides a large 
number of constraints for the comparison between model 
simulations and experimental data. Thereby, the robustness and 
the refinement of the derived aggregation mechanisms are 
significantly increased with respect to kinetic analysis that relies 
only on the comparison with a limited number of average 
quantities of the fibril population. These more refined models 
lead to a better understanding of the relationship between 
aggregation mechanisms, fibril length distribution and product 
functions. 
 
3  Atomic to mesoscopic structure of protein and 
peptide amyloids 
In the above part, we demonstrated and discussed the various self-
assembly and aggregation mechanisms of amyloid forming proteins 
and peptides. It is clear that the small differences in molecular 
aggregation and self-assembly are responsible for the formation of 
a wide variety of amyloid nanostructures. Recently, Luo and co-
workers reviewed recent advances in the protein assembly for the 
fabrication of various nanostructures by biotechnological and 
chemical strategies.250 Although that review does not focus 
specifically on amyloid fibrils, it reviews the state of the art on the 
use of proteins assembly as versatile platforms for designing 
attractive functional nanostructures. In this section, we will focus 
on the atomistic to mesoscopic structures of a number of amyloid 
assemblies, including molecular oligomers, 0D aggregates 
(nanoclusters, nanoparticles, nanotriangles, squares, and loops), 1D 
aggregates (protofibrils, nanofibrils, nanoribbons, and nanotubes), 
2D aggregates (sheets, films, and membranes), and 3D amyloid 
plaques and scaffolds. 
 
 
Fig. 6 Schematic assembly pathways of lysozyme oligomers at both 
denaturing and native temperatures. Reprinted with permission from 
Ref. 257. Copyright 2014, American Chemical Society. 
3.1 Amyloid oligomers 
Due to their ubiquitous presence in the brains of patients suffering 
from many neurodegenerative diseases and their apparent 
cytotoxicity in vitro, insoluble peptide and protein amyloid 
aggregates were assumed to be the cytotoxic culprit in these 
diseases.251 However, new evidence suggests that prefibrillar 
soluble amyloid oligomers with low molecular weight could be the 
primary toxic species responsible for neuron death in both 
Alzheimer’s and Parkinson’s disease.114, 252, 253 Although there is no 
universal consensus on what constitutes an amyloid oligomer they 
can typically be considered to possess some or all of the following 
biochemical and biophysical characteristics.254 They are molecular 
aggregates with β-sheet rich structures composed of between 2-30 
assembled monomers. They possess various sizes and morphologies, 
and are soluble in aqueous solutions. Their morphology is 
polymorphic and time-dependent and can aggregate into long, 
stable mature amyloid fibrils. Previously, a number of excellent 
review articles on the structure, formation mechanism, and toxicity 
of natural and artificial amyloid oligomers have been reported.114, 
255, 256  
 A range of techniques including AFM,257 EM,258 attenuated total 
reflection (ATR)-FTIR,259 NMR,260 and single particle confocal  
microscopy,261 have been used to investigate oligomeric structures 
and the conformational transition between oligomers and mature 
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fibrils. Mulaj et al. combined ThT fluorescence assays, static and 
dynamic light scattering (S/DLS), AFM, and ATR-FTIR to assess the 
stability, kinetics, and structure of hen egg-white lysozyme during 
its transition from oligomeric species to protofibrils and 
nanofibrils.257 They found that the amyloid oligomers and 
protofibrils but not latter stage filaments were responsible for the 
amyloid growth at both physiological and denaturing temperatures, 
as shown in Fig. 6. Their results led them to suggest that at 
physiological temperatures amyloid seeds cannot form 
spontaneously from native lysozyme monomers. Oligomer self-
replication from native monomers at physiological temperature is 
required to promote protofibril nucleation and further assembly 
into mature nanofibrils (bottom part of Fig. 6), which can also be 
created by using the denatured monomers and thus elevated 
temperatures (upper part of Fig. 6). This study outlined the self-
replication ability of amyloid oligomers and protofibrils as distinct 
assembly pathways, and is important for understanding the 
molecular mechanisms and aggregation behaviour of both 
pathological and functional amyloid materials.  
 
Fig. 7 (a-c) Crystal structure of macrocyclic peptides with (a) monomer, 
(b) dimer, and (c) tetramer. (d) Several interaction modes of dimers to 
form a tetramer. Reprinted with permission from Ref. 254. Copyright 
2011 American Chemical Society. 
 X-ray crystallography and computer simulations have been 
widely utilized to investigate the atomic structure of amyloid 
oligomers that can assemble into crystalline morphologies.254, 262, 263 
Liu and co-workers designed a series of macrocyclic peptides based 
on  A and Tau proteins (associated with AD) that formed amyloid 
oligomers with a crystalline morphology.254 Fig. 7 shows the 
atomistic structures of three macrocyclic peptides, mcVQIVFBr, 
mcAIIFL, and mcLVFFA, as monomers (Fig. 7a), dimers (Fig 7b) and 
tetramers (Fig 7c) as determined by X-ray crystallography and 
atomistic simulations. In the monomers, the interactions between 
the neighbouring strands are limited to the backbone hydrogen 
bonding (a typical β-sheet structure). For the dimers, the formed 
intermolecular β-sheets could be aligned in either parallel or 
antiparallel orientations via hydrogen-bonding interactions. In 
addition, tetramers could be formed by the complementary side-
chain interactions of dimers with different molecular packing 
geometries, as shown in Fig. 7c and d. These findings are helpful for 
understanding the assembly of amyloidogenic oligomers at the 
atomic level and offer clues for the design of structure-based 
therapeutics against amyloid diseases. More recently, the same 
authors solved the crystal structure of a toxic amyloid oligomer of 
an 11-residue segment (KVKVLGDVIEV) from the Aβ protein.262 
Separately, Domanska et al. demonstrated the utility of nanobodies 
to trap and characterize the crystalline intermediates of β2-
microglobulin amyloids by X-ray crystallography.263  
 Amyloid oligomers with distinct molecular structure and 
morphology can be created by altering the assembly environment 
(e.g. temperature, pH etc) and changing the pathways of monomer 
aggregation. Alternatively, aggregation can be modified by 
promoting interactions between protein/peptide monomers with 
additional biomolecules (eg. non-amyloid proteins or 
macromolecular sugars).264 Elucidating the structure of these 
oligomeric species at the atomic level will promote the 
understanding of formation mechanisms and toxicity of amyloid 
structures. 
 
3.2 0D amyloid aggregates 
By 0D objects we refer to aggregates/clusters, in which there is 
not a dominant dimensional feature, as in 1D or 2D objects, 
but for which self-limiting size is observed, differently from 3D 
aggregates. Numerous 0D amyloid aggregates have been 
generated in vitro. Observed morphologies include 
nanoparticles,265-268 nanospheres,269, 270 loops, triangles, 
squares, and rings.271-273  In this section, we will review the 
main preparation strategies for these nanostructures and their 
corresponding formation mechanisms. 
 
3.2.1 Nanoparticles and nanospheres  
Prefibrillar amyloid structures such as spheroidal aggregates 
(nanoparticles and nanospheres), similar to the molecular 
oligomers introduced previously, have been frequently 
proposed to be a highly cytotoxic species in many 
neurodegenerative diseases.265, 274 Silveira and co-workers 
degraded large prion protein (PrP) aggregates into smaller PrP 
nanoparticles with sizes ranging from 17 to 27 nm,265 and then 
characterised the PrP nanoparticles with DLS, non-denaturing 
gel electrophoresis, and TEM. Their finding suggested that the 
PrP nanoparticles with masses equivalent to 14-28 PrP 
molecules are the most infectious initiators for prion diseases. 
In another study, EI Moustaine et al. formed amyloid 
nanofibrils and nanoparticles from recombinant PrP at high 
pressure.266 This study provided insight into the initial 
molecular processes that lead to misfolding and eventually 
self-assembly into higher order structures. 
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Fig. 8 Typical strategies for creating 0D amyloid (a) nanoparticles and 
(b) nanoclusters: (a) Aβ oligomer self-aggregation, (b) lipid bilayer 
membrane-induced Aβ assembly. CTB is cholera toxin B subunit. ASIGN 
is Aβ-sensitive ganglioside nanocluster. Images (a,b) are reproduced 
with permission from (a) Ref. 268, Copyright 2014, American Chemical 
Society, and (b) Ref. 270, Copyright 2013, American Chemical Society. 
 Other strategies besides elevated pressure and 
degradation of larger aggregates have been investigated for 
amyloid nanoparticle fabrication. Fändrich et al. reported the 
creation of Aβ1-40 amyloid peptide nanoparticles by a simple 
self-aggregation method (Fig. 8a).267,268 Typically, Aβ1-40 with a 
concentration of 2.5 mg/mL was first dissolved in 100% HFIP, 
and the solution was diluted 10-fold with ultrapure water after 
10 min incubation. Amyloid nanoparticles with sizes ranging 
from 15 to 30 nm were formed after a further 15 min 
incubation, as shown in the TEM image in Fig. 8a. In another 
study, Guo and co-workers reported that it is theoretically 
possible for triphenylalanine (FFF)-based peptides to self-
assemble into nanospheres using the large-scale coarse-
grained molecular dynamics simulations.269 The simulations 
showed that the FFF nanospheres were formed and stabilized 
by peptide-peptide electrostatic, vdW interactions and strong 
peptide-solvent interactions. 
 Matsubara and co-workers demonstrated that Aβ1-40 
peptides can be induced to self-assemble into nanospheres on 
synapse-mimicking lipid membranes (Fig. 8b).270 They showed 
that Aβ binding and assembly was promoted on GM1 lipid 
domains. This was found to be due to the presence of an Aβ-
sensitive ganglioside nanocluster (ASIGN) within the 
glycosphingolipids (GM1) domain. The corresponding AFM 
images indicate that a thin Aβ layer and Aβ nanospheres were 
formed simultaneously. This study outlines a possible lipid 
mediated assembly mechanism of Aβ proteins that may occur 
in the AD brain. 
 
3.2.2 Annular oligomers: Loops, triangles, squares, and rings 
Other more complex 0D amyloid nanostructures have also 
been observed for a variety of amyloidogenic sequences, and 
include loops, triangles, squares, and rings. 
 Conway and co-workers reported the creation of annular 
oligomers of α-synuclein when comparing the aggregation 
behaviour of wild-type (WT) and a homo-mutant form (A53T) 
of α-synuclein connected to early-onset Parkinson’s disease.271 
The nanoscale annular oligomers were formed from equimolar 
mixtures of WT and A53T protein. It was found that the 
acceleration of oligomerization but not fibrillization is a shared 
property of α-synuclein mutations, which suggests that the 
nonfibrillar intermediates, including annular oligomers, may be 
critical in pathogenesis. Elsewhere, Hatters et al. reported the 
preparation of annular oligomers from the aggregation of 
human apolipoprotein C-II (ApoC-II).272,273 CD indicated a time-
dependent increase in the amount of β-sheet structure. After 
incubation for 48 h, the amyloid aggregates were measured 
with transmission electron microscope (TEM) and AFM, and 
ordered closed loops with a diameter of 50-75 nm were 
observed. The above studies demonstrated an alternative 
folding pathway of human apolipoproteins. Two loop 
formation models, the wormlike chain and random-walk 
approaches confirmed that the formation of annular oligomers 
is critically dependent on the fibril flexibility, which allows the 
fibrils with appropriate lengths to bend back and anneal end-
to-end to form a loop.273 In addition, Wong et al. found that 
another apolipoprotein, ApoA-I, can also form loop-like 
structures with a periodicity in the range 25-60 nm.275 
 
Fig. 9 Amyloid triangles, squares and loops of ApoC-III. (a,b) TEM 
image of loops and electron diffraction pattern, (c) AFM image of loops, 
and (d) TEM images of triangles and polyhedra. Reproduced with 
permission from Ref. 276. Copyright 2014, American Chemical Society. 
 Recently, de Messieres et al. reported that ApoC-III protein 
can aggregate into 0D amyloid triangles, small squares and 
loops.276 The formed amyloid loops (Fig. 9a and 9c) show 
ribbon-like structures consistent with helical twist, which is 
similar to the loop structures formed by α-synuclein,271 ApoC-
II,272, 273 and ApoA-I.275 The corresponding electron diffraction 
pattern (Fig. 9b) shows a typical interstrand spacing for the β-
sheet conformation, suggesting the amyloid loops are formed 
by the self-assembly of β-sheets. Other amyloid structures 
including triangles and squares were also observed, as shown 
in Fig. 9d.  
 The formation of loop-like structures in amyloid oligomers 
is related to the structures and properties of constituent 
proteins. For example, the apolipoproteins (i.e. ApoA-I, ApoC-II, 
and ApoC-III) have similar helical conformation in an annular 
morphology as when they are bound to lipid membranes,277 
and all three proteins are found on high-density lipoprotein 
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and can mediate lipids to form plaques with a similar size and 
shape to lipoprotein particles.  
 Studies have suggested that the formation of annular 
amyloid structure maybe related to the “channel 
hypothesis”.278 This hypothesis proposes that cell death in 
neurodegenerative diseases occurs via a disruption of cellular 
homeostasis due to unregulated calcium (and other ion) 
transport across the cell membrane. This is thought to occur 
due to the presence of annular oligomers of Aβ peptides or 
proteins (e.g -synuclein) that insert themselves into the cell 
membrane and creating aberrant ion channels. Ding et al. 
found that annular α-synuclein protofibrils could be produced 
when incubating spherical amyloid oligomers in solution or 
allowing them to adsorb onto ex vivo brain derived lipid 
membranes.279 In their study, two distinct oligomeric 
morphologies were formed, namely spherical and annular 
protofibrils. The annular protofibrils were formed by 
incubating spherical oligomers for prolonged periods. In 
addition, membrane-associated annular protofibrils were 
observed by binding the spherical protofibrils to brain-derived 
lipid membranes. Further studies indicated that annular 
oligomers of α-synuclein resulted in a more rapid formation of 
pores or ion-permeable channels than the soluble monomeric 
α-synuclein, providing strong evidence for the neurotoxicity of 
small annular α-synuclein oligomers.280-282 Kayed et al. studied 
the formation of annular Aβ and α-synuclein protofibrils in 
solution and on lipid membranes and proposed a possible 
formation mechanism of the annular protofibrils at the surface 
of lipid membranes.283 Their mechanism states that spherical 
oligomers first interact with the membrane, and then the 
additional oligomers are recruited to the lipid bilayer, 
conjugate with the bound oligomers to form a β-barrel pore.  
 Whilst the “channel hypothesis” does provide a compelling 
explanation for neurotoxicity via uncontrolled calcium influx 
into cells, little direct evidence has been provided either in 
vitro or in vivo.  Additionally a number of alternative 
mechanisms by which amyloid oligomers can induce similar 
cell membrane disruption have been proposed. These include 
membrane thinning,284 excessive membrane tubulation,285, 286 
or membrane extraction through amyloid-lipid co-
aggregation.170, 287 Further research into the mechanisms 
driving the assembly of annular amyloid oligomers, both in 
solution and on model cell membranes will help to elucidate 
the importance and relevance of the “channel hypothesis” in 
relation to the alternative proposed mechanisms of cell 
membrane deregulation by amyloid oligomers. 
  
3.3 1D amyloid superstructures 
In this section, the self-assembly and formation of 1D peptide 
and protein nanofibrils, twisted and untwisted nanoribbons, 
helical ribbons and nanotubes are introduced and discussed in 
detail. 
 
3.3.1 Amyloid protofilaments, protofibrils and nanofibrils 
Here, we will focus on the formation and superstructures of 
amyloid protofibrils and nanofibrils,288 we will place particular 
emphasis on fibrils possessing  twisted, helical, and chiral 
morphologies.289  
 
Fig. 10 Individual protofilaments of β-lactoglobulin aligning and 
starting to attach at specific points to form first protofibrils and finally 
mature fibrils. Reproduced with permission from Ref. 240. Copyright 
2011 Royal Society of Chemistry.  
 In general, all 1D amyloid superstructures are found to 
have a highly hierarchical morphology in which constitutive 1D 
fibril precursors combine to form mature amyloid structures. 
The terminology used for the 1D fibrillar precursors is not 
consistent through the literature, with the terms 
protofilaments or protofibrils loosely interchangable in most of 
the reports. Here we will adopt the view that protofilaments 
are the simplest mature 1D building block of amyloids, while 
protofibrils are a form of amyloid which has not yet reached 
the mature fully-formed stage. According to this terminology, 
protofilaments form individually first, then assemble into 
loosely packed protofibrils which further assemble into more 
ordered mature amyloid fibrils. Fig. 10 shows an example of 
such a process through individual snapshots resolved by 
AFM.240 The white arrows highlight the points at which 
different protofilaments started to attach and overlap to form 
protofibrils. 
 Mature (1D) amyloid fibrils are then generally formed from 
a number of intertwined protofilaments each being 2-5 nm in 
diameter and up to a few µm in length.235 Variations in the 
packing of these protofilaments result in a wide variety of 
morphologies all with potentially different functions. Insight 
into the packing mechanisms can be achieved with various 
nanoscale analytical techniques. 
 For example, Stroud et al. studied the structure and 
properties of oligomers of Aβ1-42 with XRD, TEM, CD, FTIR, and 
chromatography.290 They found that the peptide molecules 
could stack into short protofilaments consisting of pairs of 
helical β-sheets, which wrapped around each other to form a 
superhelical structure. In another example, Dearborn and co-
workers utilized cryo-TEM and scanning transmission electron 
microscopy (STEM) to study the in vitro self-assembly of α-
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synuclein.291 They found that protofibrils have a typical size 
with length of 7.5 nm and width of 2.5 nm. 
 In the following of this section we will discuss the various 
1D morphologies observed and how they may affect their 
biological, biomedical or nanotechnological functions. 
 
3.3.2 Twisted ribbons and helical ribbons 
Many multi-filamentous morphologies have been observed 
including twisted ribbons, helical ribbons and rippled 
structures. Twisted ribbons are characterized by a saddle-like 
(Gaussian) curvature; helical ribbons on the other hand are 
characterized by a mean curvature but zero Gaussian 
curvature: in other words, they can be wrapped around a 
cylinder. The transition from twisted to helical ribbon in 
amyloid is now well understood and been reviewed already 
extensively.154, 292 In general, a twisted to helical transition is 
observed upon increase in the number of protofilaments 
(width to thickness ratio), as a consequence of a different way 
to store bending and torsional energy by twisted vs helical 
ribbons. Helical ribbons can finally close into nanotubes 
eliminating the extra energy associated with edge line tension. 
This mechanism and the associated entire series of transitions 
have been observed both in peptide and protein-based 
amyloids.29, 206, 293 More common, however, is the presence of 
one individual polymorphic form observed at distinct 
timepoints. 
 
Fig. 11 Twisted and helical amyloid ribbons: (a) Left-handed β-
lactoglobulin nanofibrils with multistranded twisted filaments. 
Reprinted with permission from Ref. 233. Copyright 2010, Nature 
Publisher. (b) Cross-β amyloid TTR105-115 fibril with triplet atomic-
resolution structure. Reprinted with permission from Ref. 294. 
Copyright 2013, National Academy of Sciences. (c) Twisted right-
handed helical ILQINS hexapeptide ribbon. Reproduced with 
permission from Ref. 297. Copyright 2014, American Chemical Society. 
(d) Twisted double-helical peptide ribbon, Reprinted with permission 
from Ref. 298. Copyright 2009, Wiley-VCH Verlag GmbH & Co. (e) 
Amyloid-inspired rippled β-sheet ribbons by the co-assembly of 
enantiomeric amphipathic peptides. Reprinted with permission from 
Ref. 299. Copyright 2012, American Chemical Society. 
 α-synuclein fibrils have been shown to co-exist as left- and 
right-handed helical ribbons with differing pitches.77 Adamcik 
et al. examined the different stages of aggregation throughout 
heat-denatured β-lactoglobulin amyloid fibril assembly with 
single-molecule AFM and theoretical analysis.233 They found 
that the mature fibrils have a multistranded left-handed 
twisted morphology. Fig. 11a presents the typical AFM images 
and corresponding coarse-grain molecular dynamics 
reconstructions of the left-handed helical β-lactoglobulin fibrils. 
The β-lactoglobulin nanofibrils were shown to have 
persistence lengths of between 1-4 µm and maximum heights 
of 2, 4, 6, 8, and 10 nm for 1, 2, 3, 4, and 5 twisted filaments, 
respectively. In addition, the helical pitch of nanofibrils 
showed clear proportional increase from 35-135 nm with 
increasing filament number. This work provided a general 
model for understanding amyloid fibril assembly into a twisted 
ribbon morphology. In another study, Fitzpatrick and co-
workers investigated atomic structure and assembly of fibrils 
formed from the TTR105-115 peptide. As with α-synuclein and β-
lactoglobulin, TTR105-115 was found to assemble into mature 
fibrils via hierarchical assembly of β strands of peptide 
molecules into protofilaments which further intertwined to 
form mature fibrils with a twisted ribbon structure (Fig. 
11b).294  
 In general, there is a well-defined linear relationship 𝐿 ∝ 𝑛 
between the periodicity 𝐿 of twisted ribbon amyloids and the 
number of constitutive protofilaments, 𝑛 .233 Using coarse 
grained simulations, Assenza et al. showed that the 
relationship between twisted ribbon periodicity and the 
number of protofilaments has a pseudo-linear behavior at 
small 𝑛, i.e. L~(3n2-7)½. When the number of protofilaments 
increases and the fibrils approaches maturity the relationship 
with periodicity approaches a truly linear behaviour.295 This 
has led to the conclusion that this behaviour is a universal 
mesoscopic signature of amyloid fibril polymorphism. 
 Twisted and helical ribbons with different structures have also 
been created by selecting specific peptide sequences and 
controlling their molecular self-assembly. For example, Uesaka et al. 
investigated the self-assembly of the histidine (his)-containing 
helical peptides of the form A3-Hisn-B, where A is a hydrophilic 
polysarcosine chain, and B is a hydrophobic helical 
dodecapeptide.296 Dependent on the pH of the peptide solutions 
the molecular assemblies formed different morphologies including 
twisted ribbons, helical ribbons, and nanotubes. The A3-His2-B 
peptide formed twisted ribbons, helical ribbons, and nanotubes at 
pH 3.0, 5.0, and 7.4, respectively, whilst A3-His-B only formed helical 
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ribbons at pH 3.0. The pH dependent morphological changes were 
explained by variations in electrostatic repulsion, which in turn 
affected the molecular packing of the peptides. This study showed a 
very effective pH-responsive strategy for creating adjustable 1D 
amyloid structures by controlling the intermolecular interactions.  
 Lara and co-workers reported that a hexapeptide (ILQINS) 
identified as being an amyloidogenic sequence in left-handed 
helical ribbons formed from hen egg white lysozyme self-assembles 
into right-handed helical ribbons and crystals.297 At short incubation 
times multi-stranded right-handed helical ribbon structures were 
observed (Fig. 11c). At longer incubation times the right-handed 
ribbons were almost entirely replaced by aggregates with a 
crystalline structure. Hamley and co-workers demonstrated the 
formation of left- and right-handed twisted helical amyloid ribbons 
by assembling the peptide fragment (KLVFF) modified with two β2-
Alanine residues (β2Aβ2A-KLVFF), as shown in Fig. 11d.298 In some 
cases, the left- and right-handed twisted helices were intertwined 
into a double-helix amyloid ribbon, as shown in the inset image. The 
formation of helical ribbons is ascribed to both functional motifs of 
the designed peptide, in which the KLVFF motif is responsible for 
the self-assembly to cylindrical fibrils, and the β-amino acids are 
crucial for the formation of helical nanoribbons. A sequence of 
twisted fibrils, helical ribbons and nanotubes were observed as 
kinetic states during the aggregation of the capped version of this 
peptide, globular structures also being observed as the initial 
state.293 The closure into nanotubes was very slow, being observed 
only after several weeks.   
 Swanekamp and co-workers reported the formation of 
rippled β-sheet L/D-cofibrils from the coassembly of two 
enantiomeric amphipathic peptides, L-(FKFE)2 and D-(FKFE)2, as 
shown in the inset of Fig. 11e.299 The L-(FKEF)2 peptide self-
assembled in water into left-handed helical fibrils, whilst the D-
(FKFE)2 peptide self-assembled into enantiomeric right-handed 
fibrils (TEM image of Fig. 11e). The equimolar mixing of L-
(FKFE)2 and D-(FKFE)2 created a new fibril type, which contains 
alternating L- and D-peptides in a rippled β-sheet orientation. 
 Lashuel and co-workers demonstrated the creation of 
polymorphic β-sheet quaternary structures including fibrils and 
ribbons by using a small number of peptidomimetics.300 They found 
that the distribution of quaternary amyloid structures could be 
adjusted by manipulating the pH, buffer conditions, and ionic 
strength. Their study indicated that it is possible to control both the 
self-assembly of designed peptide structures and their lateral 
interactions to create untwisted amyloid ribbons.  
 Adamcik and co-workers created large multistranded amyloid 
ribbons from the microtubule-binding fragment 
(VQIVYKPVDLSKVTSKCGSLGNIHHK, known as R3) of Tau protein.301  
Tau does not aggregate spontaneously in vitro, but it undergoes 
aggregation in the presence of polyanions such as heparin.302 The 
peptide motif, VQIVYK, plays critical roles for the self-assembly and 
formation of β-sheet amyloid aggregates of Tau. Therefore, the self-
assembly of R3 in both the presence and absence of heparin was 
investigated. In the presence of heparin, R3 fibrils with a normal 
twisted fibrillar morphology were rapidly formed as seen by AFM, 
TEM and strong ThT binding. In the absence of heparin, aggregation 
was much reduced, as evidenced by decreased ThT binding, 
however amyloid ribbons consisting of large numbers of laterally 
associated protofilaments were observed (Fig. 12a). Increasing 
incubation times up to 1 week demonstrated the continuous 
growth of the multifilamentous ribbons eventually forming giant 
multistranded amyloid ribbons with 2D laminated structures 
(composed of over 45 laterally associated protofilaments of 350 nm 
total width).  
 
Fig. 12 Multistranded amyloid ribbons: (a) Tau protein R3 ribbon, 
Reprinted with permission from Ref. 301. Copyright 2016 Wiley-VCH 
Verlag GmbH &Co. (b) Multistranded hIAPP20-29 ribbon, Reprinted with 
permission from Ref. 303. Copyright 2013, National Academy of 
Sciences. (c,d) Lysozyme (c) and β-lactoglobulin (d) ribbons, Reprinted 
with permission from Ref. 206. Copyright 2011, American Chemical 
Society. (e) Amelogenin ribbon, Reprinted with permission from Ref. 
305. Copyright 2016, Nature Publishing Group. 
 Recently, Zhang et al. studied the self-assembled structures of 
hIAPP20-29, the amyloidogenic core fragment relevant to type-II 
diabetes, by quantitative nanomechanical AFM.303 They provided 
strong evidence of the coexistence of fibrils with flat ribbon and 
helical ribbon morphologies, as shown in Fig. 12b. As in the work of 
Adamcik et. al.,301 the ribbons show clear striations along their long 
axis, indicating the presence of multiple parallel protofilaments 
(inset of Fig. 12b). AFM-based force-volume and nanoindentation 
measurements indicated that the flat ribbon structure has higher 
stiffness than helical ribbons, suggesting that the core of the helical 
ribbons were hollow. 
 Some proteins, such as lysozyme,206 β-lactoglobulin,206 and 
amelogenins,304-306 can also form multistranded amyloid ribbons 
over time. Lara et al. introduced a general self-assembly mechanism 
for converting hydrolysed globular lysozyme and β-lactoglobulin 
into multistranded amyloid ribbons (Fig. 12c and d).206 After long 
periods of time (up to 100 hours) multistranded ribbons with widths 
up to 173 nm were observed due to a modular lateral assembly of 
around 17 protofilaments. This study provided novel insight into the 
fibrillation mechanisms of globular proteins and amyloid 
polymorphism. Recently, Carneiro and co-workers showed that 
recombinant human full-length amelogenin protein (rH174) can 
self-assemble into amyloid-like ribbons both in vitro and in vivo.305 
In the presence of calcium and phosphate, rH174 assembled into 
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highly aligned ribbons on glass substrate (Fig. 12e) with widths of 23 
nm regular peak-to-peak distance of approximately 69 nm. 
 The above studies show that multistranded amyloid ribbons can 
be fabricated from a range of proteins or amyloidogenic peptides 
(i.e. R3, KLVFF, and VQIVYK). Examples such as this increase our 
understanding of how peptide sequences and the reaction 
conditions affect the final morphology of the assembled structures. 
A detailed knowledge of the factors underpinning assembly into 
mature fibrils should allow the routine rational design of amyloid 
forming peptides containing specified amino acid sequences 
additional to the amyloidogenic core. This will enable us to tailor 
the structure and function of the fabricated assemblies for a range 
of applications. Up until now such there are only a few examples of 
such functionalized peptide sequences,307, 308 largely due to the 
difficulty in predicting the amyloidogenicity of the modified 
peptides. 
  
3.3.3 Amyloid nanotubes 
Amyloid protein and peptide nanotubes are a particularly 
interesting class of amyloid nanostructure, due to their 
uniform dimensions, hollow architecture, and potential for 
modification, which have led to many potential applications 
for materials science, nanotechnology, and biomedicine. A 
comprehensive review of the synthesis and 
bionanotechnological applications of various protein and 
peptide nanotubes is available,309 in which the structure, 
design and corresponding nanotube assembly mechanisms of 
proteins (lysozyme, Hcp1, TRAP, and others) and surfactant-
like peptides have been demonstrated and discussed. In this 
section, we will focus on the studies of several novel amyloid 
protein and peptide nanotubes first described after the 
publication of the above review. 
 Amyloid nanotubes can be created by either the closure of 
helical ribbons precursors as discussed above (section 3.3.2) or 
by molecular design of single proteins or peptide building 
blocks.310-312 For example, Zhao et al. reported that a 
symmetric amphiphilic peptide with the sequence of KI4K 
could assemble into nanotubes in aqueous solution.311 The 
created peptide nanotubes have typical diameters in the range 
of 80-160 nm and lengths on the order of µm. In addition, they 
found that the peptide assemblies could be converted from 
nanotubes to nanofibrils by increasing the acetonitrile 
concentration in the assembly system. In another study, 
Brodin and co-workers reported the design and synthesis of 
protein nanotubes with adjustable diameters by using a single 
tetrameric Zn8R4 building block that created by mixing 
disulphide-linked protein dimer (R2) with 4 equivalents of 
Zn2+.312 The formation and morphology of the nanotubes was 
mediated by altering the concentration of Zn2+ causing the 
rapid formation of nanotubes with a width of 48±3 and 20±2 
nm, respectively. The initial formation of the Zn8R4 building 
blocks was crucial for the formation of nanotubes as the direct 
mixing of 10-fold Zn2+ with R2 in the first step resulted in only 
amorphous aggregates. This work showed it is possible to 
kinetically dictate the self-assembly of protein building blocks 
to desired nanostructures by tuning the intermolecular 
interactions with metal coordination. 
 
Fig. 13 (a-c) Supramolecular co-assembly for the formation of amyloid 
peptide nanotubes with controllable dimensions: (a) co-assembly 
mechanism of FF and Boc-FF, (b) SEM image of peptide nanotubes 
with a FF/Boc-FFF ratio of 5:1, and (c) Length distribution. Reproduced 
with permission from Ref. 313. Copyright 2016, American Chemical 
Society. (d,e) Co-assembly of amyloid amphiphilic peptide-based 
molecules to form multiwalled nanotubes: (d) co-assembly mechanism, 
and (e) TEM image of peptide nanotubes. Reproduced with permission 
from Ref. 314. Copyright 2014, American Chemical Society. 
 Amyloid nanotubes can also be prepared by the 
supramolecular co-assembly of two peptide-based building 
blocks.313,314 The integration of two types of building blocks 
allows the fabrication of nanomaterials with complex structure 
and extended biophysical properties. Adler-Abramovich and 
co-workers formed peptide nanotubes with controllable 
physical dimensions313 from the co-assembly of two 
diphenylalanine (FF) based building blocks. Aqueous solutions 
of FF and Boc-FF (N-(tert-butoxycarbonyl)-L-Phe-L-Phe-COOH), 
were mixed at various molar ratios (Fig. 13a). Increasing the 
Boc-FF concentration in the co-assembly system resulted in a 
systematic decrease in the length of the assembled nanotubes 
as shown in Fig. 13b and c. This work revealed a simple and 
effective strategy for creating peptide nanotubes with 
controllable length distribution through the co-assembly of 
two peptide building blocks, providing a template for 
molecular engineering at the nanoscale. 
 Lin and co-workers produced multi-walled amyloid 
nanotubes by mixing two oppositely charged drug-peptide 
amphiphilic molecules.314 The peptide moiety GNNQQNY, a 
key β-sheet forming sequence derived from the yeast prion 
Sup35, was modified by an anticancer drug camptothecin (CPT) 
to design the drug-peptide building blocks. Two lysine (K) and 
two glutamic acid (E) residues were added to the C-terminal of 
the drug-peptide chain to adjust the overall amphiphilicity and 
pKa, as shown in Fig. 13d. They found that qCPT-Sup35-K2 
(here “q” means four CPTs are bound to the peptide moiety) 
and qCPT-Sup35-E2 could co-assemble into nanotubes, but 
dCPT-Sup35-K2 (here “d” means two CPTs are bound onto the 
peptide moiety) and dCPT-Sup35-E2 could only co-assemble 
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into nanofibrils (Fig. 13d). When qCPT-Sup35-K2 and qCPT-
Sup35-E2 were mixed, nanotubes with uniform morphology 
were clearly observed as shown in Fig. 13e. The created CPT-
peptide nanotubes have an outer diameter of about 123 nm 
and wall thickness of approximately 25 nm, which suggest the 
presence of multiple bilayers in the assembled structure. 
Theoretically, the created drug-peptide nanotubes possess a 
36% fixed CPT loading, and therefore could have promising 
application in drug delivery and cancer therapeutics. 
  
3.4 2D amyloids (sheets, films, and membranes) 
3.4.1 2D protein amyloids 
Amyloid fibrils generally possess very high mechanical strength 
and adhere well to various substrates. These features make it 
possible to create 2D amyloid assemblies using simple post-
assembly treatment techniques. 
 A number of different post-assembly processes have been 
investigated to fabricate 2D amyloid films. These include 
amyloid stacking,315 filtration,316 and self-assembly at the air-
water interface.317, 318 Lysozyme nanofibril films were created 
by stacking pre-formed nanofibrils onto a 
polytetrafluoroethylene film (Fig. 14a),315 and β-lactoglobulin 
nanofibril films were fabricated via vacuum filtration of 
solutions of β-lactoglobulin nanofibrils (Fig. 14b).316 
 
Fig. 14 Typical methods for the fabrication of 2D protein amyloids: (a) 
stacking, (b) filtration, and (c) self-assembly at air-water interface. 
Image (a-c) are reproduced by permission from (a) Ref. 315, Copyright 
2010, Nature publishing Group, (b) Ref. 316, Copyright 2015, American 
Chemical Society, and (c) Ref. 317, Copyright 2016, Royal Society of 
Chemistry.  
 Jordens and co-workers reported the formation of β-
lactoglobulin amyloid fibril films at an air-water interface.318 
The assembly mechanism was found to follow a complex non-
equilibrium process leading to a crowded interface and a 
viscoelastic 2D film.319, 320 The structure of the interface could 
be further defined by combining long protein nanofibrils with 
short protein linear aggregates, as shown in Fig. 14c.317 
Experiment and simulation results indicated that the short 
protein aggregates orient perpendicular to the long nanofibrils 
at very short distances and parallel to the axis of nanofibrils at 
intermediate distances, as shown in the AFM image in Fig. 14c. 
Liquid crystalline 2D bimodal systems such as this may have 
interesting technological applications but are complex and 
hard to control due to a large number of long-range non-
covalent interactions affecting the self-assembly process. Thus 
studies such as this are very helpful to better understand and 
guide liquid crystal structures at an interface, and to unveil the 
process of formation of amyloid biofilms, as discussed later in 
this review. 
 
Fig. 15 (a) Schematic illustration of the proposed mechanism for amyloid 
nanofilm formation. (b-d) Schematic strategies for lysozyme fibril 
nanofilm formation (b) on the surface of immersed materials (solid/liquid 
interface) and (c) at the aqueous solution surface (vapor/liquid interface). 
(d) The contact-printing technique to deposit the free-floating amyloid 
nanofilm onto water-sensitive substrates Reproduced with permission 
from Ref. 321. Copyright 2015, Wiley-VCH Verlag GmbH & Co. 
 Recently, Wang et al. exploited the conformation change of 
lysozyme after breaking down its disulfide bond by tris(2-
carboxyethyl) phosphine (TCEP) to induce heterogeneous 
nucleation and assembly (Fig. 15a).321 The assembled lysozyme 
fibrils spontaneously concentrated at both the solid-water and 
water-air interfaces (Fig. 15a,b), and the films formed at the 
water-air interface could easily be converted to free floating films 
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(Fig. 15c) transferred to the surface of a hydrogel and contact 
printed onto a water sensitive substrate (Fig. 15d).   
 
3.4.2 2D peptide amyloids 
Amyloid nanofibrils fabricated from short peptide sequences 
have also been utilized to fabricate 2D  structures including 
membranes,322 nanosheets,323, 324 and films.325,326 This is 
typically achieved by adjusting the assembly conditions (ionic 
strength, pH or physical stimulations) to promote the 
formation of 2D substrates.  
 The Zhang group reported the spontaneous self-assembly 
of a self-complementary oligopeptide (EAK16) to form a stable 
macroscopic membrane.322 They found that peptides with 
alternating hydrophilic and hydrophobic amino acid residues 
readily form β-sheet structures and then aggregate into stable 
membranes dependent on the ionic strength of the solution. 
The assembled membranes have very high stability to heat and 
extreme pH (acid and alkaline) due to the formation of 
complementary ionic bonds between glutamic acid (E) and 
lysine (K) residues. This work paved the way for the fabrication 
of nanofibrous peptide structures with controllable self-
assembly dependent on their sequence.  
 
Fig. 16 a) Amino acid sequence of Aβ1-42 and molecular structure of 
Aβ16-22; b) AFM image and height analysis of self-assembled amyloid 
nanosheets; c) structural modal of the KLVFFAK nanosheet. 
Reproduced with permission from Ref. 323. Copyright 2015, National 
Academy of Sciences. 
 Dai and co-workers demonstrated the formation of 
amyloid nanosheets from a mutated form of Aβ16-22  (KLVFFAK) 
(Fig. 16a).323 The nanosheets were typically a few microns long, 
several hundred nm wide and around 2.2 nm thick (Fig. 16b). 
Increasing the ionic strength of the peptide solution promoted 
the formation of more uniform nanosheets. Based on their 
experimental observations and molecular dynamics 
simulations, the authors hypothesised that the peptide 
molecules within the nanosheet stand upright to form a 
monolayer (peptide length = 2.2 nm). The nanosheet then 
grows in two dimensions along both the fibril axis (a’) via the 
main-chain hydrogen bonds and the zippering axis (b’) via the 
side-chain steric hydrophobic interactions (Fig. 16c). This work 
shows that the functionality of amyloid nanosheets can be 
tuned by replacing the amino acid side chains at the periphery 
but retaining the core nanosheet-forming sequence (LVFFA). In 
another study, Hamley and co-workers reported that the 
amphiphilic peptide (Ala)6Arg could self-assemble into 3 nm-
thick peptide sheets at low concentration in aqueous 
solutions.324 The self-assembly of the peptide and the 
formation of sheets are driven by the amphiphilic sequence 
design of the peptide molecule with unique conformation and 
the electrostatic properties of the arginine headgroup.  
 Physical stimulations can also mediate the self-assembly of 
peptide molecules and promote the subsequent formation of 
2D amyloid films. For instance, Pan and co-workers developed 
a simple, effective and environmentally friendly method of 
fabricating nanofibrous films from Aβ16-22, via argon glow 
discharge.326  
 
3.5 3D amyloid plaques and scaffolds 
 3D insoluble deposits in the brain (i.e. Lewy Bodies in PD, and 
A plaques or Tau tangles in AD) are major pathological 
hallmarks in many neurodegenerative diseases.327 These 
deposits typically have length scales spanning from several to a 
few hundred microns and are composed predominantly of 
amyloid fibrils, with other assorted biomolecules (lipids, sugars 
etc). Currently visualization of these deposits (often post 
mortem) represents one of the only definitive methods to 
diagnose a number of diseases including Alzheimer’s or 
Parkinson’s. Therefore, a considerable amount of research has 
focused on developing in vivo and in vitro brain imaging 
protocols to detect and observe these deposits. A number of 
different imaging techniques including magnetic resonance 
imaging (MRI),328 positron emission tomography (PET),329 near 
infrared (NIR) imaging,330 and FTIR microscopy,331 have been 
utilized to investigate the formation and growth of amyloid 
plaques. Benseny-Cases and co-workers used micro-FTIR 
spectroscopy to observe the in-situ co-localization of amyloid 
senile plaques in tissue samples of human brains affected by 
Alzheimer’s disease.331 They found that the oxidization of lipid 
in tissues is associated with the aggregation of peptides and 
the formation of amyloid plaques. The tissue samples from 
non-Alzheimer’s disease samples showed lower level of lipid 
oxidation, which indicated that the oxidative capacity of 
amyloid peptides or proteins may play a crucial role in the 
formation of amyloid plaques. 
In addition to natural amyloid plaques, artificial amyloid 
3D structures (multilayers,332 and microgels333, 334) have been 
reported. Qin et al. utilized an Aβ peptide derivative with a 
diphenylalanine moiety (Ne-RGDFF-OH) to create peptide 
nanofibrils that assembled into supramolecular hydrogels at 
both pH 8 and 6.5.332 The self-assembly of the designed 
peptide was defined by three distinct motifs. The naphthyl 
group (Ne) provides the hydrophobic force to enhance the 
self-assembly ability in aqueous solutions, the FF motif serves 
as the core amyloidogenic sequence, and the RGD sequence (a 
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sequence found in the ECM protein fibronectin) acts as both 
an acceptor and a donor of hydrogen bonds. In addition, the 
RGD sequences can promote biocompatibility and cell 
attachment. Their results indicated that the designed peptide 
nanofibrils could be further adjusted into catenulate 
microfibers (forming a row or chain), multilayered amyloid 
plaques, and hydrogels by controlling the drying conditions of 
the amyloid nanofibril solution. 
 
Fig. 17 Synthesis of amyloid 3D lysozyme microgels from amyloid fibril 
networks: a) water-in-oil microgels, and b) oil-in-water microgels. (c-f) 
Typical (c,d) 3D reconstructions of the confocal images and (e,f) cryo-
SEM images of a) water-in-oil and b) oil-in-water microgels, 
respectively. Reproduced with permission from Ref. 334. Copyright 
2015, American Chemical Society. 
   Amyloid nanofibrils can be also fabricated to form 3D 
microgels.333 Recently, the Knowles group established a class 
of microgels based on amyloid protein fibrils by combining 
their inherent self-assembly process with microscale 
structuring techniques.334 Both water-in-oil and oil-in-water 
microgels were prepared by forming microdroplets of a 
concentrated aqueous solution of lysozyme protein, as shown 
in Fig. 17a and b.  For the formation of water-in-oil microgels, a 
microfluidic device was fabricated to create microdroplets of 
lysozyme solution encapsulated in an immiscible oil phase (Fig. 
17a). After incubation, protein monomers assembled into 
protein nanofibril gels, which were recovered from the oil 
phase by extensive washing. Confocal fluorescence microscopy 
(Fig. 17c) and cryo-SEM (Fig. 17e) images indicated that 
networks of protein nanofibrils were formed in the interior of 
the microgels. When the phases are reversed (i.e water-in-oil 
becomes oil-in-water) hollow microgels were formed (Fig. 17b). 
The corresponding confocal fluorescence microscopy (Fig. 17d) 
and cryo-SEM (Fig. 17f) images showed that in this case the 
lysozyme monomers were located at the oil/water interface, 
and thus the fibrillar network structure was formed on the 
outer shell of the oil-in-water microgels. Protein microgels 
based on amyloid nanofibrils may have interesting applications 
for enhanced drug delivery due to their high biocompatibility 
and biodegradability. 
 
3.6 Summary on the characteristic length scale of various 
amyloid structures 
In parts 3.1-3.5, we have comprehensively reviewed the 
formation of various amyloid structures with morphologies 
including pre-fibrillar oligomers, nanoparticles, fibrils, films, 
and plaques. The various amyloid systems discussed and their 
dominant morphologies, length scale and assembly conditions 
are presented in Table 1. 
 
Table 1 Summary of the types, species, length scales, and formation 
conditions of amyloid nanostructures. 
 
Amyloid  
Type 
Species Length Scale Assembly 
Condition 
Ref 
oligomers lysozyme Monomer to fibril pH=3, 70°C 257 
 cyclic peptide monomer, dimer, 
tetramer 
20 mM PBS, pH 7 254 
 KCKCLGDVIEV 6-mers/2.2 nm -- 262 
 β2-microglobulin -- pH=7.5, 20 mM Tris 263 
0D     
NPs PrP 17-27 nm self-assembly 265 
NPs Recom-PrP 20 nm self-assembly 266 
NPs Aβ1-40 15-30 nm self-aggregation 268 
sphere FFF-peptide 10-13 nm self-assembly 269 
sphere Aβ1-40 10-60 nm membrane-assembly 270 
loop α-synu-A53T H=2-4 nm, D=23-
55 nm 
self-assembly  271 
loop ApoC-II H=2.1 nm, W=12 
nm, D=50-75 nm 
self-aggregation  
in PBS buffer 
272 
triangle ApoC-III D=35-77 nm NaPi buffer 276 
1D     
protofibril β-lactoglobulin H=3 nm, L= 500 
nm 
pH=2, 90 °C, D2O 240 
protofibril Aβ1-42 13-28 nm PBS, 37 °C 290 
protofibril α-synuclein L=7.5, W=2.5 nm HEPES, 37 °C 291 
helical fibril β-lactoglobulin L=0.5-15 µm, 
H=2-6 nm 
pH=2, self-assembly 233 
fibril TTR105-115 H=7-16 nm, L=1-3 
µm 
aceton/water, pH=2 294 
ribbon ILQINS W=63-87 nm, 
L=5.57 µm 
pH=2, 90  °C 297 
ribbon AAKLVFF W=17.5 nm self-assembly 293, 298 
cofibril (FKFE)2 D=8.2±1.0 nm, L= 
a few 100 nm 
self-assembly in water 299 
ribbon R3 W=147 nm, L=a 
few µm 
self-assembly in buffer 301 
ribbon hIAPP20-29 H=7.4 nm, 
L=several 100 nm 
self-assembly 303 
nanotube KI4K D=80-160 nm, L= 
a few µm 
self-assembly in water 311 
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nanotube Zn8R4 D=20-48 nm, L= a 
few µm 
Zn2+-induced assembly 312 
nanotube FF, Boc-FF L=10 µm 90  °C , H2O, assembly 313 
nanotube CPT-Sup35 D=123±28 nm, 
L= a few µm 
1:1 MeCN/H2O 314 
2D     
film lysozyme a few mm stacking 315 
film β-lactoglobulin adjustable filtration 316 
film β-lactoglobulin adjustable self-assembly at air-
water interface 
317 
nanosheet Aβ16-22 H=2.3 nm, W=500 
nm, L= a few µm 
self-assembly 323 
sheet A6R thick=3 nm, L/W= 
a few 100 nm 
self-assembly in solution 324 
3D     
plaques Aβ1-42 Several-100 µm aggregation 331 
multilayer Ne-RGDFF-OH hydrogel assembly at pH 8/6.5 332 
microgels lysozyme 2-60 µm microdroplet 334 
 
 In addition, referring to previous reports by Knowles and 
Mezzenga,32, 33 an illustrative chart of amyloid materials across 
all relevant length scales is shown in Fig. 18. 
 
Fig. 18 Length scale of various amyloid structures from monomer to 
oligomers, 0D, 1D, 2D, and 3D. 
 
4 Manifold functionality of biological and 
artificial protein/peptide amyloid materials 
In this section, we will present and discuss the fabrication of 
biological (biofilms) and functional hybrid amyloid materials. 
 
4.1 Fabrication and functions of biological amyloids 
Natural protein and peptide amyloid materials show higher 
stability, mechanical strength, and increased resistance to 
protease biodegradation compared to their corresponding 
protein and peptide monomers. These properties have been 
utilised in nature to create “functional” amyloids with beneficial 
physiological functions. Numerous examples of functional 
amyloid systems have been found in bacteria, plants and 
mammals.335-338 Additionally, the above physical characteristics 
make synthetic amyloids attractive structural components for the 
formation of functional biomaterials with wide ranging 
applications. 
 
4.1.1 Amyloid-based biofilms 
Biofilms are complex bacterial communities embedded in a 
predominantly proteinaceous ECM which protects bacteria from 
the surrounding environments.339 Amyloid protein fibrils have 
been identified as a major structural component of many 
biofilms.340  To better understand the fundamental processes 
underpinning biofilm formation, amyloid formations in bacterial 
biofilms (curli fibrils) have been investigated for growing films of 
E. coli.14, 341 In the formation process of the biofilm, CsgA subunits 
are secreted by E. coli and self-assemble into amyloid curli fibrils, 
whilst CsgB subunits serve as nucleator proteins to anchor the 
curli fibrils to the bacterial membrane (Fig. 19a).14  
 
Fig. 19 (a) Formation mechanism of curli fibrils in E. coli biofilm. 
Reprinted with permission from Ref. 14. Copyright 2008, Wiley-VCH. (b) 
3D projection (upper) and side view (lower) CLSM images of S. 
Typhimurium biofilms with growth period of 24, 48, and 72hs. (c) 
CLSM image of 72 h biofilm with DNA staining. Reproduced with 
permission from Ref. 345. Copyright 2015, Elsevier Inc. 
 Biofilm formation can also be affected by a range of other 
protein subunits other than CsgA and CsgB.342-344 For example, 
Ostrowski et al. found that a small protein named YuaB serves 
both an exopolysaccharide and an accelerator for mediating the 
formation of TasA amyloid fibrils during biofilm formation.342 
Herbst et al. investigated the formation of biofilms with the 
Gram-negative bacterium, P. aeruginosa, and found that the 
proteome of this bacterium is tightly associated with amyloid 
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fibril formation, the distribution of fibrils, biofilm formation, and 
proteolytic activity.344 Studies have also shown that DNA may 
play an important role in the formation of biofilms, Gallo and co-
workers reported the formation and roles of curli-DNA 
composites in S. Typhimurium pellicle biofilms formed at the air-
liquid interface (Fig. 19b).345 Microscopy images of the 72 h S. 
Typhimurium biofilms showed high concentrations of stained 
DNA (Fig. 19c), indicating that extracellular DNA (eDNA) either 
released by dying bacteria or actively released into the ECM 
serves as an important component for the formation of these 
biofilms. Furthermore, ThT fluorescent assays showed that eDNA 
accelerates the polymerization of curli fibrils, inhibiting their 
degradation by DNAase and creating potent immunogenic 
complexes, which were seen to activate a number of different 
immune cell types. This work highlighted a role of curli-DNA 
composites in stimulating the innate and the adaptive immune 
system. 
 The formation of amyloid-based biofilms can be mediated by 
adjusting the physiochemical environment of the growing 
bacteria. For instance, Wu and co-workers investigated the 
formation of biofilms of E. coli at the air-liquid interface,346 and 
found that the curli fibrils present in the biofilms result in a 
significant increase in their strength, viscoelasticity, and electrical 
resistance. The same authors studied the effects of chemicals 
such as dimethyl sulfoxide and ethanol on amyloid biogenesis 
and biofilm formation. They showed that the presence of these 
small molecules increased the formation of the E. coli biofilm.347 
Other environmental signals (e.g. ionic strength and pH) can also 
affect the formation of biofilms. Taglialegna et al. reported that 
the Bap protein of S. aureus assembles into functional amyloid 
nanofibrils and can be induced to form a biofilm matrix at low pH 
and in the presence of low concentrations of Ca2+ ions.348 
Increased Ca2+ concentration favours a more stable Bap 
conformation leading to the inhibition of amyloid formation. This 
relationship between Ca2+ concentration and amyloid formation 
could have implications in the design of antibacterial materials 
and therapeutics. 
  
4.1.2 Amyloid hydrogels and aerogels 
Hydrogels are water swollen polymeric networks formed by long 
range non-covalent interactions of self-assembled nanofibrils. 
Amyloidogenic proteins and peptides have been shown to make 
useful molecular building blocks for the design and synthesis of 
hydrogels.349 Due to their relative ease of synthesis and 
biocompatibility these hydrogels show a wide variety of 
applications in diverse fields including: cellular therapies, drug 
delivery, and tissue repair.67, 350 In order to successfully fabricate 
amyloid hydrogels two conditions must be met. First, the protein 
or peptide monomers must have the ability to form amyloid 
fibrils in aqueous solutions and second, the fibrils must be able to 
be synthesised at sufficient concentration to promote gelation.19  
 Amyloid hydrogels have been formed from a variety of 
amyloid proteins including elastin,351 α-synuclein,352 lysozyme,353, 
354 and β-lactoglobulin.355-357 Bhak et al. reported the synthesis of 
amyloid hydrogels derived from α-synuclein fibrils with a curled 
morphology (so called CAF, or curly amyloid fibrils). They showed 
that CAF hydrogels have potential applications as a matrix for 
enzyme entrapment.352 In their study, they found that under 
normal self-assembly conditions (200 rpm, 37 °C, and 100 h), α-
synuclein preferred to form straight amyloid fibrils (SAF) that did 
not readily form hydrogels (Fig. 20a). CAF that did undergo 
gelation were created by isolating α-synuclein granules formed in 
the middle of the lag phase of the aggregation pathway. The 
granules were subjected to centrifugal membrane filtration to 
form CAFs (Fig. 20b). These hydrogels were characterised via ThT 
binding assays and confocal microscopy (Fig. 20c). The authors 
proposed that these α-synuclein hydrogels could have potential 
applications in fields as diverse as tissue engineering, drug 
delivery, nanofiltration, and biosensing. Knowles and co-workers 
fabricated lysozyme hydrogels loaded with drugs.315 The addition 
of beta-adrenoceptor antagonists into the lysozyme hydrogel 
altered the nanostructure of lysozyme amyloids and affected 
drug release profiles. This study suggests that hydrogel-based 
drug carrier architecture can be adjusted to obtain desirable 
release performance by careful selection of structural promoters 
and disruptors of amyloids. 
 Bolisetty et al. discussed the gelation of β-lactoglobulin 
amyloid fibrils and proposed that β-lactoglobulin fibrils could 
undergo both an isotropic-nematic and a sol-gel phase transition 
with increasing fibril concentration or ionic strength.357 This work 
sheds light on the dynamic behaviour of biological colloidal 
system and opens new directions in the fabrication of amyloid 
gels. 
 
Fig. 20 (a-c) Amyloid protein nanofiber hydrogel: (a) formation 
mechanism, (b) SEM and (c) fluorescence images. Reproduced with 
permission from Ref. 352. Copyright 2010 Elsevier Ltd.  (d-f) Amyloid 
peptide nanofiber hydrogel: (d) formation mechanism, (e) optical 
image of hydrogel, and (f) AFM image. Reproduced with permission 
from Ref. 19. Copyright 2015 Elsevier Ltd. 
 Hydrogels have also been prepared from Aβ amyloid fibrils. 
Jacob et al. studied the formation of self-healing amyloid 
hydrogels from a series of peptides based on the high 
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aggregation prone C-terminus of Aβ1-40 and Aβ1-42.19 They found 
that a number of sequences only formed hydrogels when the 
amino acid sequence was conjugated to an aromatic Fmoc 
protecting group. Additional long range aromatic stabilisation (π-
π stacking) offered by the Fmoc groups (Fig. 20d) was found to be 
a major driving force promoting gelation of these peptides. The 
addition of a fluorescent dye (Nile Red) into the peptide amyloid 
hydrogel inhibited gelation, suggesting that Nile Red blocks 
exposed hydrophobic sites on the formed amyloid fibrils and 
reduces their non-covalent interactions. The corresponding 
optical (Fig. 20e) and AFM (Fig. 20f) images identify the formation 
of amyloid hydrogels with 3D structure composed of nanoscale 
fibrous networks. 
 The additional stabilisation offered by the conjugated Fmoc 
group allows very short peptide fragments from Aβ to form 
amyloid-like hydrogels. For instance Fmoc-dipeptide hydrogels 
(FF and KK) have been formed based on β-sheet self-assembly 
and intermolecular π-π association.358 Hydrogels have also been 
formed through the self-assembly of non Fmoc containing short 
peptides.359-361 Tena-Solsona et al. demonstrated that the self-
assembly and co-aggregation of tetrapeptides containing 
alternate aromatic and polar amino acid residues (Z-FDFD, Z-
DFDF, and others, where Z denotes a benzyloxycarbonyl group) 
can lead to hydrogel formation, which can be used to screen 
positively charged Lys residues involved in amyloid misfolding.359 
In a further study, pH-responsive hydrogels were formed from Z-
FDFD, Z-FKFK, and Z-KFKF.360 
 An interesting extension of the hydrogel, is its “dry” 
homologue, the so-called aerogel. In a recent study, Nystrom et 
al. demostrated that β-lactoglobulin amyloids can form ultralight 
aerogels composed solely of β-lactoglobulin amyloid fibrils and 
air.362 This new material is among the lightest materials ever 
created and fully epxloits the rigidity and versatily of β-
lactoglobulin amyloid fibrils. To create the dry form, the water 
content of β-lactoglobulin amyloid hydrogels was solvent-
exchanged with ethanol to produce an alchogel. Then, exploiting 
the fact that ethanol is fully miscible with supercritical CO2, they 
removed the liquid phase by supercritical CO2 processing, leading 
to the final amyloid aerogels. Excitingly, these aerogels can be 
used to template the formation of hybrid materials with unique 
properties, leading, for example to the lightest form of gold ever 
produced to date. These gold aerogels were formed by 
combining β-lactoglobulin amyloid fibrils and gold single crystals 
and fabricating the aerogels as outlined above. The resultant 
aerogels contain no more than two percent solid mass. Beside 
being the lightest gold material ever produced, the gold aerogels 
have additonal properties unseen in solid gold, such as photonic, 
fluorescent and catalytic properties. This example and the others 
preceding it illustrate the endless possibilities available when 
designing materials using amyloids as building blocks. 
  
4.2 Fabrication and functions of artificial amyloid-based hybrid 
materials 
Amyloid fibrils generally display multiple, identical, and 
periodically spaced binding sites for small molecules along their 
surface. This makes them an exciting prospect for the design of 
amyloid materials functionalised with specific chemistries post-
assembly. In this section, we will introduce the preparation and 
fabrication of 1D, 2D, and 3D functionalised or hybrid 
nanomaterials. 
 
4.2.1 1D amyloid-based hybrid materials 
Lysozyme, Aβ, curli proteins and a number of other systems have 
been used to fabricate 1D amyloid hybrid systems. Whilst 
amyloids make ideal substrates for hybridisation with additional 
functional materials, care must be taken that additional materials 
do not modify amyloid aggregation altering the balance of 
hydrophobic and electrostatic interactions within the forming 
fibrils.  
 
4.2.1.1 Amyloid-nanoparticle 
One of the most studied amyloid hybrid systems is the amyloid-
nanoparticle hybrid. Such hybrids allow the fabrication of 
nanoparticle-decorated amyloids with specified material 
properties. Alternatively, nanoparticles have been used as 
therapeutic targets for disease related amyloids with the aim of 
inhibiting amyloid aggregation. Typically, the formation of 
amyloid-nanoparticle hybrids is based on metal or metal 
compound nanoparticles.363-365 Bolisetty et al. reported the 
synthesis of hybrids formed by dispersing negatively charged iron 
oxide (Fe3O4) magnetic nanoparticles in positively charged β-
lactoglobulin solutions at acidic pH. Depending on the pH, 
different hybrid aggregates are formed, at pH 3 amyloid fibrils 
with their surface decorated with nanoparticles were observed 
and at pH 4.5 only spherical nanoclusters were observed.366 Liao 
et al. studied the influence of gold nanoparticles (AuNPs) on Aβ 
fibrillation and found that they could alter the observed 
fibrillization pathways.367 AuNPs added to preformed Aβ fibrils, 
caused fragmentation of the fibrils. AuNPs possessing negative 
surface potential inhibited Aβ fibrillation and redirected 
assembly into off-pathway intermediates. Such anionic AuNPs 
could potentially have applications as AD therapeutics preventing 
assembly into toxic species.367  
 More complex nanoparticles have also been investigated.  
For instance, Yoo et al. reported that thioglycolic acid-stabilized 
CdTe nanoparticles are capable of efficient inhibition of amyloid 
formation.136 Inhibition occurred as CdTe nanoparticles 
preferably bind to oligomers but not monomers, halting the 
aggregation process at this stage. This paper highlights a 
potential issue with such amyloid inhibitors; indeed, preventing 
fibrillization may be relatively simple, but if it is at the expense of 
creating more amyloid oligomers, extreme care must be taken to 
ensure that the oligomers formed are not themselves highly 
cytotoxic. Other nanoparticles have also been used to reduce 
amyloid aggregation kinetics. Anand et al. designed capsaicin-
capped silver nanoparticles (AgNPs) to suppress albumin 
aggregation.364 Interestingly, assembly inhibition was not 
observed in the presence of isolated capsaicin molecules or 
unmodified nanoparticles, suggesting a co-operative effect 
between the silver nanoparticles and capsaicin coating. 
 Polymeric nanoparticles have also been shown to affect the 
fibrillation kinetics of amyloid fibrils. Brambilla et al. showed that 
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PEGylated nanoparticles with long in vivo retention times bind 
strongly to the Aβ1-42 peptide.368 Structural analysis revealed 
that binding occurred through a non-specific binding of the 
PEG polymer on the surface of the NP (Fig. 21a). Simulations 
revealed that the PEG chains wind around the helical peptide 
between residues 1-25 and more loosely interact with the helix 
at residues 26-42 and at the -turn (Fig. 21b and c). To 
evaluate the role of oxygen atoms in the PEG, it was replaced 
with a fully alkylated polymer chain. This fully saturated 
polymer chain did not wind around the helix (1-25) but bound 
only with the termini of both helices, clearly indicating the 
importance of the oxygen atoms in such polymers.  
 
Fig. 21 (a) Atomistic model of a PEG chain docked to Aβ1-42. The chain 
interacts with both hydrophobic as well as hydrophilic residues of the 
peptide and forms a spiral structure. (b) Best 50 conformations of the 
PEG chain (purple) docked to Aβ1-42 (orange), and (c) alkyl PE chain 
(purple) docking on Aβ1-42 (orange). Images (a)-(c) are Reproduced with 
permission from Ref. 368. Copyright 2012, American Chemical Society. 
(d-g) AFM (bottom row) images of the β-lactoglobulin amyloid fibrils 
(d) and fibrils decorated by gold (e), silver (f), and palladium (g) 
nanoparticles after the respective metal salt reduction by NaBH4. 
Images (d)-(g) are reproduced with permission from Ref. 370. 
Copyright 2014, American Chemical Society. 
 Amyloid fibrils have also been used for metallization and 
mineralization experiments, and the fabrication of amyloid-
nanoparticle nanohybrids. Previously, Wei and co-workers 
showed it was possible to functionalise the surface of amyloid-
like fibrinogen nanofibrils with AuNPs.369 Bolisetty et al. were 
able to decorate β-lactoglobulin amyloid fibrils (Fig. 21d) with 
Au (Fig. 21e), Ag (Fig. 21f), and Pd (Fig. 21g) NPs via metal salt 
reduction by NaBH4.370 Hamley et al. examined the labelling of 
amyloid nanofibrils created from the self-assembly of a 
surfactant-like peptide Ala10His6 (hexa-histidine connected with 
an oligo-alanine sequence) with NTA functionalized AuNPs in the 
presence of Ni.371 Pazos and co-workers reported a one-pot 
synthesis for the nucleation of uniformly sized and spatially 
ordered AgNPs using supramolecular nanofibrils formed by 
peptide-amphiphiles.372 Aldehyde moieties at the N-terminus 
could reduce two silver ions to form Ag2 clusters without the 
need for an external reducing agent or additives to control the 
nucleation process.  
 
4.2.1.2 Amyloid-quantum dots 
Similar to nanoparticles, QDs have been shown to inhibit amyloid 
fibrillation. Xiao et al. reported that N-acetyl-L-cysteine capped 
QDs (NAC-QDs) are capable of disrupting the fibrillation of insulin 
amyloid assemblies due to hydrogen bonding between the NAC-
QDs and the fibrils.373 Ng et al. suggested that NAC-QDs may act 
as neuro-protective agents through fibrillation inhibition and a 
reduction in the formation of reactive oxygen species.374  
 
Fig. 22 (a) Schematic representation of the GQDs used for inhibiting the 
aggregation of Aβ1-42 peptides. (b) The kinetics of Aβ1-42 aggregation as 
monitored by the thioflavin T fluorescence in the absence of GQD or 
presence of GQD. Reproduced with permission from Ref. 375. 
Copyright 2015 Royal Society of Chemistry.  (c) AFM images of the fibrils 
obtained from mixtures of (i-iii) QD-bAS (QD/bAS = 1/40), and (iv) α-
synuclein alone. Scale bars: 10 μm. Reproduced with permission from 
Ref. 376. Copyright 2009, American Chemical Society. 
 Liu et al. demonstrated graphene QDs (GQDs) can efficiently 
inhibit the aggregation of Aβ peptides.375 This is thought to be 
either due to binding of the negatively charged GQDs to the 
central hydrophobic motif and/or positively charged histidine 
residues present on Aβ1-42 (Fig. 22a and b). Further studies 
revealed that the inhibition efficiency of the GQDs decreased 
with increasing surface negative charge, indicating that the 
hydrophobic interactions are likely to be dominant. In some 
cases, QDs can accelerate the aggregation of amyloid proteins. 
Roberti et al. demonstrated that the aggregation of α-synuclein 
at high concentrations was enhanced by adding multivalent QDs 
(Fig. 22c).376 This is likely due to aggregation seeding initiated by 
the high local concentrations displayed at the surface of the QDs. 
Fig. 22c (i-iii) shows that the QDs functionalised with biotinylated 
α-synuclein (bAS) are incorporated into α-synuclein fibrils 
resulting in increased aggregation.  
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 The inherent fluorescence of QDs opens many new potential 
applications for amyloid fibrils-QD hybrids, for example they 
could be used as fluorescent biosensors, or for bioimaging or 
diagnostics. NHS modification of CdSe-ZnS core-shell QDs has 
been used to detect the formation of amyloid protein fibrils in 
solution by fluorescent measurements after binding to the 
fibrils.94 Quan et al. reported a red-emitting fluorescent probe 
constructed by PEGylated QDs further functionalized with 
benzotriazole (BTA) that facilitated the targeting to the β2 
position of Aβ fibrils with high affinity, enabling the sensitive 
detection of amyloid fibrils.377 Due to a combination of the 
greater fluorescent quenching of QDs and the higher affinity of 
the BTA, QD-PEG-BTA probes were able to achieve more 
sensitive detection than conventional thioflavin derivatives. Su et 
al. used peptide nanofibrils decorated with QDs as an 
intracellular fluorescent imaging agent.378 Cellular internalization 
of the nanofibril-QD hybrids was promoted by increased 
interactions between the cationic fibrils and the slightly 
negatively charged outer leaflet of the cell membrane. In a 
further study, they created  novel functional hybrid materials 
based on the conjugation of GO, peptide nanofibrils, and 
GQDs.379 
  
4.2.1.3 Amyloid-hydroxyapatite 
Due to broad functionalization possibilities, long contour lengths, 
exceptional mechanical properties, accurately controlled growth 
and ease of synthesis, amyloid fibrils are ideal candidates to act 
as biomimetic materials, performing similar biological functions 
to fibrous networks such as fibronectin or collagen. In vivo bone 
regrowth occurs in the presence of collagen-hydroxyapatite (HA) 
composites, thus in the fields of tissue engineering and 
regenerative medicine there is a strong desire for biomaterials 
that can mimic the properties of these composites.380 The Stupp 
group demonstrated that one-dimensional cylindrical and fibrillar 
nanostructures were able to direct the growth of oriented HA 
crystals, while flatter nanostructures failed to reproduce the 
orientation found in biological systems.74, 380 By adjusting pH, 
concentration and ionic strength, Wei et al. prepared amyloid-
like fibrinogen fibrils in the absence of Ca2+ and thrombin.95 
These fibrils were mineralised to form amyloid-HA composites 
proving that self-assembled fibrinogen nanofibrils can mimic 
collagen and serve as a building block for HA-based biomaterials 
for bone tissue regeneration applications. Wang et al. fabricated 
a HA scaffold via layer-by-layer assembly of graphene oxide (GO) 
nanosheets and preformed fibrinogen nanofibrils.381 After 7 days 
of mineralization in simulated body fluid, the GO-nanofibril 
surface was uniformly covered with branch-like apatite minerals 
that didn’t appear on a bare GO substrate. Therefore, it appears 
that the amyloid nanofibrils provided a structural foundation and 
surface functional groups for the growth of HA crystals. A second 
generation of amyloid peptide nanofibrils was designed with 
specific motifs present on the surface of the fibril to provide the 
nucleation sites for HA mineralization.382 Using these fibrils and 
GO nanosheets, they fabricated a nanohybrid scaffold designed 
to promote mineralisation. The second generation nanohybrids 
enhanced nanoscale apatite crystal growth leading to the 
formation of HA spheres with a diameter of 4 μm.  
 
Fig. 23 (a) Schematic representation of the fabrication of bone-mimetic 
composites based on amyloid fibril and HA platelets. (b) TEM image of β-
lactoglobulin amyloid fibrils. (c-e) SEM image of HA platelets (c), surface 
(d) and fracture sections (e) of the amyloid-based composite with 60 wt% 
brushite platelets. Reproduced with permission from Ref. 383. 
Copyright 2014, Wiley-VCH Verlag GmbH & Co. 
 In order to be useful biomimetic scaffolds for bone re-growth, 
amyloid-HA hybrids should not only promote mineralization but 
they must also display the high levels of mechanical stiffness 
required to provide the load bearing ability of newly formed 
bone. Adopting a simple filtration procedure, Li et al. 
fabricated a highly laminated structure composed of β-
lactoglobulin  and/or lysozyme amyloid fibrils and HA platelets 
(Fig. 23a).383 The formed fibril network possessed a homogenous 
and compact surface and the resultant biomimetic bone grown 
on the networks had similar Young’s modulus and density to 
human bone (Fig. 23b-e). More importantly, these scaffolds 
promoted the growth of human osteoblast cells, providing a 
compelling example of amyloid-based biomimetic bones.  
 
4.2.1.4 Amyloid-carbon materials 
Various carbon nanomaterials including fullerenes (C60), carbon 
nanotubes (CNTs), graphene, and GO have been investigated for 
their ability to inhibit amyloid assembly.384, 385 Due to the 
presence of multiple benzene rings in the majority of carbon 
nanomaterial structures, hydrophobic interactions are thought to 
play a key role in the inhibitory ability of carbon nanomaterials. In 
a comprehensive review, Li and Mezzenga discussed how C60, 
CNT and GO affect amyloid fibrillation and the formation of 
amyloid-carbon material hybrids.384 It is expected that the 
conformation and chemical behaviour of the Aβ peptide will 
change in the presence of single-walled carbon nanotubes 
(SWNTs) due to the adsorption of the peptide onto the 
hydrophobic surface of the SWNTs. Importantly, the cytotoxicity 
of cells cultured in the presence of SWNTs coated with Aβ 
peptides was drastically reduced compared to cells cultured with 
the Aβ peptide alone.386  
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Fig. 24 Formation of amyloid nanofibril-MWNT hybrid: (a) Schematic 
illustrations of functionalization of CNTs with amyloid fibrils. (b-d) TEM 
images of hybrids consisting of functionalized MWNTs (black arrows) and 
amyloid fibrils (white arrows) at 0.1 wt % with (b and c) covalent and (d) 
noncovalent functionalization. Reproduced with permission from Ref. 
355. Copyright 2012, American Chemical Society. 
 To enhance the binding of amyloids to carbon nanomaterials, 
attempts have been made to modify the nanomaterials with 
reactive polymers or small molecules. For example, Li and 
Mezzenga introduced sulfonic functional groups on the surfaces 
of multi-walled carbon nanotubes (MWNTs) promoting 
interactions with β-lactoglobulin fibrils (Fig. 24a).355 The 
negatively charged functionalised MWNT surfaces promote 
complex formation with the positively charged β-lactoglobulin 
fibrils. Beside complementary chemistry, other factors such as 
the persistence length (of both MWNTs and fibrils) and ionic 
strength are important for the fabrication of hybrid amyloid-
carbon materials. If the persistence lengths of both MWNTs and 
amyloid fibrils are not similar, the mismatch leads to a 
misalignment of the fibrils along the MWNTs contour lengths due 
to a high content of SO3- (Fig. 24b and 24c). However, an 
appropriate content of SO3- would make individual MWNTs 
match several amyloid fibrils at different positions, as shown in 
Fig. 24d. 
 The surface modification of carbon nanomaterials plays an 
important role in the design of multifunctional amyloid-carbon 
material composites.381, 382, 387  For instance, positively charged 
lysozyme fibrils can bind to GO sheets, providing binding sites for 
negative charged AuNPs.388 The charges from GO and lysozyme 
become partially nullified, making the hybrids ideal platforms for 
immobilizing additional molecules such as enzymes to afford 
additional functions. 
 Mahmoudi et al. found that the large available surface area 
of GO sheets is able to delay the process of Aβ fibrillation via 
adsorption of amyloid monomers.389 In addition, the protein 
coating layer can create a protective shell on the surface of the 
GO sheets, resulting in an increase in the amyloid assembly lag 
time. Yang et al. reported that graphene nanosheets could 
penetrate and extract a large number of peptides from pre-
formed amyloid fibrils.390 This leads to the intriguing question of 
whether graphene or GO sheets could have therapeutic 
applications and potentially reverse the amyloid formation 
process in neurodegenerative diseases. However, it is likely that 
such therapies would either need to be injected directly into the 
brain or be able to cross the BBB, factors that complicate the 
development of such therapeutics. Very recently, Castelletto and 
co-workers reported the fabrication of a hybrid biomaterial 
based on the co-operative self-assembly of polysaccharide 
sodium alginate with PA (C16-KKFF) and subsequently adding 
GO.391 The created hybrid biomaterial showed excellent 
bioactivity and high mechanical strength. 
   
4.2.1.5 Amyloid-biomacromolecules 
Functionalizing amyloid fibrils with specific biomolecules such as 
proteins and sugars may have significant biomedical applications. 
For instance, networks of amyloid based materials can be 
produced that mimic various biological tissues such as muscles or 
the cornea.392, 393  
 
Fig. 25 (a) CR and NBT assays confirm the amyloidogenic features and the 
formation of amyloid-DOPA hybrid. (b) TEM images of unmodified and 
modified amyloid nanofibrils with biomolecules. (c) Schematic 
presentation of the measurement of the adhesion force between amyloid 
nanofibrils and biomolecules with AFM force spectroscopy. 
Representative AFM image showing modified Mfp5-CsgA fibres 1 h after 
deposition on a mica surface. Reproduced with permission from Ref. 
394. Copyright 2014, Nature Publishing Group. 
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 Zhong et al. reported strong underwater adhesives 
constructed by co-polymers of tyrosine containing mussel foot 
proteins (Mfps) of Mytilus galloprovincialis and CsgA protein 
(which forms curli fibrils in E. coli).394 The co-polymers all formed 
fibrous structures, but the nitro blue tetrazolium (NBT) assay 
turned purple (to confirm the presence of the adhesive moiety 
DOPA) only when the Mfps proteins were modified with 
tyrosinase (which converts tyrosine residues to DOPA) (Fig. 25a 
and b). To assess the underwater adhesion of the adhesive fibres, 
AFM tips modified with silica, gold or polystyrene surfaces were 
used. The strongest adhesion was found with silica tips and 
tyrosinase-modified fibres, suggesting that the amyloid domains 
of the adhesive fibres not only provided a high surface area for 
contact but could also modulate how the Mfp domains interact 
with the substrates and achieve different adhesion levels (Fig. 
25c). In another case, Dubey et al. identified that amyloid 
nanofibrils can promote co-aggregation of other proteins, which 
also explained the mechanism of coexistence of two amyloid-
linked diseases in individual patients.395 However, both 
aggressive co-aggregation and cross-seeding reactions between 
different proteins occurred only at 70 °C.  
 There are many studies based on physiochemical properties 
and functions of amyloid fibril based materials.396 Nikiforov et al. 
studied electromechanical coupling of amyloid fibrils in both 
prokaryotic and eukaryotic cells.397 They found that the 
mechanical properties of the fibril and the electrical double layer 
at the fibril- water interface are responsible for its 
electromechanical response. Ling and co-workers combined 
regenerated silk fibrils from Bombyx mori (B. mori) fibroin with 
amyloid fibrils produced in vitro from β-lactoglobulin.398 By either 
adding inorganic nanoparticles or by selectively removing one of 
the fibrous constituents via enzymatic reactions, they further 
explored how the Young’s moduli, porosity and stimuli-
responsive features of the resulting hybrid materials can be 
controlled. The authors also showed that these membranes 
could be used for molecular-weight dependent separation, 
pointing at possible future applications of these porous scaffolds 
as protein-based separation membranes. 
 
4.2.2 2D amyloid-based hybrid materials 
The Young’s modulus of many amyloidogenic 2D films are similar 
to those of many rigid proteinaceous materials found in nature, 
(e.g. keratin and collagen).315 Thus, when functionalized with 
additional biologically relevant molecules, 2D amyloid-hybrid 
materials can be fabricated that mimic both chemical and 
structural facets of biology.  
 Based on amyloid fibrils and silk fibroin fibrils, Ling et al. 
designed a multifunctional membrane decorated with magnetic 
nanoparticles.398 The formed membrane was transparent and 
homogenous under cross-polarized light, with -strands of silk 
fibroin running parallel to the film plane and the amyloid fibrils in 
a perpendicular orientation (Fig. 26a and b) as detected by Wide-
angle X-ray scattering (Fig. 26c-e). The addition of positively 
charged magnetic nanoparticles resulted in the fabrication of a 
homogenously distributed film combining dual magnetic and 
moisture responsiveness (Fig. 26f and g). Hydration of the 
membrane resulted in a reduction in rigidity and allowed for 
cyclic shape printing and recovery on repeated wetting and 
drying cycles. Upon applying a magnetic field to the hydrated film 
the membrane underwent a bending motion and maintained its 
shape after removal of the field and drying. Layer-by-layer 
deposition of silk proteins and amyloid fibrils has also been 
employed to create an immunosensing platform capable of 
detecting Aβ1-40.399 Multilayers containing 1, 3 and 5 bilayers of 
silk fibroin and Aβ1-40 fibrils were fabricated that showed linear 
responses to increasing Aβ1-40 antibody concentrations via cyclic 
voltammetry.  
 
Fig. 26 (a) Schematic orientation of β-sheets and β-strands in silk fibroin 
fibrils and amyloid fibrils. (b) Schematic illustration and cross-polarized 
light observation image of silk fibroin fibrils and amyloid fibrils composite 
film. (c-e) 2D-WAXS patterns of the films containing (c) 100% silk fibroin 
fibrils, (d) 100% amyloid fibrils and (e) 5:5 silk fibroin fibrils:amyloid fibrils. 
(f) Magnetic functionalization and tensile properties of the film (silk 
fibroin fibrils:amyloid fibrils:magnetic nanoparticles weight ratio of 
70:10:20), as prepared by vacuum filtration. (g) Shape-memory properties 
of the magnetic composite film when exposed to the combined presence 
of an external magnetic field and water. Reproduced with permission 
from Ref. 398. Copyright 2014 Wiley-VCH Verlag GmbH & Co. 
 Wu et al. used the previously discussed amyloid-GO 
immobilization platform to immobilise Au nanocatalysts and 
enzymes.388 This integrated system maintained the catalytic 
activity of the immobilized AuNPs, and was used as an 
electrochemical sensor for colorimetric glucose sensing. Yan et 
al. also reported a new approach combining electron-induced 
molecular self-assembly with simultaneous metal nanoparticle 
formation.400 The peptide motif KLVFF (Aβ16-20) was combined 
with metal ions and assembled into membranes in the presence 
of an argon plasma. The argon plasma resulted in the reduction 
of the metal ions forming homogenously dispersed metal NPs 
that decorated the underlying film of amyloid fibrils.326 Such 
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hybrid amyloid-nanoparticle films may have important 
applications in heterogeneous metal catalysis. This has been 
recently demonstrated with amyloid-nanoparticle porous 
membranes, capable of securing a continuous flow of a feeding 
solution which undergoes instantaneous heterogeneous catalysis 
within the hybrid membranes.316 
  2D amyloid hybrids have also been used to elucidate a better 
understanding of the mechanisms of bacterial biofilm formation. 
Nguyen et al. fused functional peptide domains onto the CsgA 
protein, resulting in a self-assembled network of curli fibres 
resembling the wild-type system.401 This molecular engineering 
strategy should provide diverse artificial functions to synthetic 
hybrid amyloid biofilms. Additional peptide sequences could be 
introduced to the biofilm to provide various functionality 
including biomineralization, substrate adhesion, and protein 
immobilization. Using similar strategies, robust 2D materials with 
programmed functions could be fabricated with applications as 
large-scale engineered biomaterials. 
  
4.2.3 3D amyloid-based hybrid materials 
Utilizing amyloid-based molecules as building blocks to develop 
3D functional materials with well-defined architectures and 
chemistry is a growing area of interest.402, 403  
 
Fig. 27 (a) layered organization of amyloid fibrils and gold platelet hybrid 
nanocomposites. Reproduced with permission from Ref. 404. Copyright 
2013, Wiley-VCH Verlag GmbH & Co. (b) An illustrative description of the 
development of a photoluminescent peptide-QD hydrogel through the 
self-assembly of Fmoc-FF building blocks and their PL quenching 
associated with the enzymatic detection of analytes. Reprinted with 
permission from Ref. 406. Copyright 2014, Wiley-VCH Verlag GmbH & 
Co. 
 3D hybrid amyloid materials are typically designed based on 
one or several kinds of lower dimensional materials. For example, 
Lara and co-workers fabricated 3D structures from single crystal 
nanoplatelets, protein nanotubes and ribbons.29 By changing the 
procedure by which water is removed from the system, the same 
building blocks can be organized into organic-inorganic hybrid 
films of unique physical properties, composed of well-organized 
layered 2D single crystal gold nanoplatelets and 1D amyloid fibrils 
(Fig. 27a).404 Adhikari and Banerjee incorporated graphene and 
reduced graphene oxide (RGO) into amyloid networks resulting in 
stable transparent hydrogels.405 In this system, two kinds of Fmoc 
protected dipeptides, namely, Fmoc-YD-OH and Fmoc-FD-OH 
formed composite hydrogels without the presence of any 
external stabilizing agent. The hydrogels were stabilized via 
inherent π-π interactions between the Fmoc group, the aromatic 
side chains of Tyr and Phe residues and the RGO sheets. A 
number of stimulus-responsive amyloid hydrogels have also been 
investigated. For instance, by combining MWNTs decorated with 
sulfonic groups and β-lactoglobulin nanofibrils pH-responsive 
hydrogels were fabricated that reversibly form gels at acid pH.355  
 Metallized and small molecule modified nanofibrils also offer 
the possibility to create hydrogels for applications in 
nanotechnology. In a recent study conducted by the Stupp 
group,372 bacterial growth was inhibited by hydrogels formed 
from peptide nanofibrils decorated with AgNPs. Kim et al. formed 
meso-tetra(4-pyridyl) porphine (TPyP) and Fmoc-diphenylalanine 
(Fmoc-FF) composite nanofibrils.406 The four pyridyl groups at the 
meso-functional position of TPyP and carboxylic and hydroxyl 
groups of Fmoc-FF promoted hydrogel formation (Fig. 27b). 
   
5 Various applications of amyloid-based hybrid 
nanomaterials 
Thanks to their unique physiochemical properties, amyloid based 
nanomaterials, have many potential applications in a number of 
fields including biomedical engineering, tissue engineering, 
energy storage and catalysis. In this section we will review some 
of the most promising and exciting examples of where amyloid 
materials have been incorporated into functional devices. 
 
5.1 Biomedical engineering 
Historically, research on amyloids has largely focused on 
obtaining an improved understanding of the mechanisms causing 
toxicity in neurodegenerative diseases. However, in more recent 
times there has been a growing interest in using non-toxic 
amyloid assemblies for biomedical engineering applications.33, 407 
Some of the key studies in this area will be outlined in this 
section.  
 Due to the regular distribution of labile groups on their 
surface, many amyloid fibrils are amenable to functionalization 
with a broad range of moieties and molecules. For instance, 
Bolisetty et al. showed that amyloid fibrils can be used to 
enhance nanoparticle transfection into living organisms by 
incubating gold, silver, and palladium nanoparticle-decorated 
amyloid fibrils in the presence of living dendritic or MCF7 cells 
and confirmed their ability to cross the cell membrane and be 
uptaken into living cells (Fig. 28a).370 Mains et al. explored 
lysozyme amyloid hydrogels loaded with a series of small 
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molecule beta adrenoceptor antagonists such as atenolol, 
propranolol and timolol.354 Atenolol was shown to disrupt β-
sheet content within the hydrogel whilst propranolol had the 
opposite effect and timolol had little effect. This research 
highlighted the need for careful selection of structure promoters 
and disruptors for drug delivery applications. The conjugation of 
amyloid fibrils with drug compounds may also be a useful 
strategy to create long-acting drug depots and provide controlled 
release systems preventing rapid clearance from the body.17  
 
Fig. 28 (a) Schematic representation of the internalization and 
transport of metal nanoparticle-decorated amyloid fibrils into living 
cancer cells. Reprinted with permission from Ref. 370. Copyright 2014, 
American Chemical Society. (b) Proposed coating mechanism of SEVI 
fibrils with amyloid-binding oligomers. These coatings prevent the 
direct interaction of HIV-1 with SEVI fibrils and prevent SEVI-mediated 
enhancement of viral infection in cells. Reprinted with permission from 
Ref. 413. Copyright 2012, American Chemical Society. 
 Cheetham et al. designed a drug-peptide conjugate from Tau 
fibrils and the anticancer drug CPT (mCPT-mal-Tau), which 
formed discrete, stable, well-defined nanofibrils and nanotubes 
capable of quantitative drug loading.408 The drug loading in the 
peptide nanostructures increased from 23% in non-fibrous 
controls to 38%. The corresponding drug release experiments 
indicated that the self-assembled drug-loaded peptide 
nanostructures released the bioactive form of the drug and 
enhanced the in vitro efficacy against a number of cancer cell 
lines.  
 Further examples of amyloid based drug delivery systems 
include a camptothecin (KCK-CPT) prodrug, that self-assembles 
initially into nanotubes, and upon complexation with hyaluronic 
acid into arrays of nanofibrils which form micelles upon 
dilution.409 The hyaluronic acid-coated micelles were then seen 
to undergo efficient endocytosis into cancer cells in vitro where 
they were degraded back to the nanofibrous morphology in the 
endosome. Finally, the KCK-CPT prodrug was converted to the 
active form by glutathione (GSH) in the cytoplasm, inducing 
apoptosis in the cancer cell. Waku and Tanaka showed that self-
assembling peptide nanofibrils can be used as potential delivery 
agents for vaccines.410, 411 Highly antigen-loaded nano-assemblies 
were formed by conjugating antigens to β-sheet-forming 
peptides. The antigen-loaded peptide nanofibrils were taken up 
more efficiently by murine RAW264 cells compared to 
monomeric cell penetrating peptide-modified antigenic peptides, 
possibly because their size is more suitable for cellular uptake. 
Improved intracellular antigen delivery using a system such as 
this may promote a more efficient induction of the immune 
response required for effective vaccination to occur.  
 Due to their small size and nanoscale regularity, amyloid 
oligomers have been explored as potential nanomaterials for 
improved targeting and medical imaging. By conjugating either 
fluorescent molecules or superparamagnetic iron oxide (FeO) 
particles with oligomeric Aβ, Kumar et al. observed that the 
oligomeric hybrids specifically targeted macrophages in an in 
vitro co-culture of peripheral blood mononuclear cells and 
macrophages.268 Of particular interest might be both the 
visualization of disease-associated accumulation of macrophages 
in vivo by MRI and the imaging of atherosclerotic plaques to 
assess the extent of cardiovascular disease. Very recently, Lock 
and co-workers synthesised an anticancer drug, Pemetrexed 
(Pem), conjugated onto the peptide sequence (FE).412 The PemFE 
conjugate spontaneously self-assembles into nanofibrils and 
hydrogels under physiological conditions. The location, 
distribution, recovery, and drug release of injected PemFE 
hydrogels was successfully monitored by chemical exchange 
saturation transfer (CEST) MRI. This work proposed a potential 
strategy to monitor the in vivo distribution and release of drugs 
by using supramolecular design and self-assembly. 
 Capule et al. reported that oligovalent amyloid-binding 
molecules can reduce the enhancement of human 
immunodeficiency virus-1 (HIV-1) infection. The designed 
amyloid binding molecules competitively bind to semen-derived 
enhancer of virus infection (SEVI) fibrils preventing SEVI-
mediated enhancement of viral infection in cells (Fig. 28b).413 
Yolamanova et al. demonstrated that amyloid fibrils fabricated 
from a 12-residue peptide (enhancing factor C) boosted virus 
infection of HIV-1 by a factor of four compared to naturally 
occurring SEVI fibrils.414 This reduced virus infection is due to the 
formation of an electrostatic ‘nanobridge’ between the virion 
and the cell. Such amyloid based nanomaterials may significantly 
improve our ability to direct retroviral gene transfer in basic 
research and clinical applications. 
  
5.2 Tissue engineering 
Materials that can accurately replicate the structure of the micro- 
and nano-scale fibrous network that surrounds many cell types, 
the ECM, have many applications in tissue engineering and 
cellular therapies. For instance, ECM mimicking scaffolds may aid 
the culture of large volumes of clinically relevant therapeutic cells 
in vitro, or be used as implantable scaffolds for cell growth and 
tissue regeneration in vivo. Networks of amyloid fibrils assembled 
from either natural proteins or synthetic peptides are promising 
candidates for such materials as they possess similar 
morphological and mechanical properties to the fibrillar proteins 
that make up the ECM (e.g. fibronectin, collagen, and laminin). 
Additionally, they can be inexpensive to produce in the large 
ARTICLE Journal Name 
32 | J. Name., 2013, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
 
 
volumes required for clinical applications and are well suited to 
chemical functionalization with peptide sequences (typically from 
ECM proteins) that may promote cell adhesion, growth or 
differentiation (in stem cells). 
 In 2004, the Stupp group integrated the IKVAV sequence (a 
cell binding sequence from laminin) with a PA system to fabricate 
nanofibrous hydrogels. The density of the IKVAV presentation on 
the surface of the nanofibrils was three orders of magnitude 
higher than for laminin in the ECM. Furthermore, neural 
progenitor cells cultured in these hydrogels were seen to 
efficiently differentiate into neurons.415 Various other amyloid 
based systems decorated with cell adhesion sequences have also 
been reported. For instance, Gras et al. modified a 10-residue 
peptide fragment (TTR105-115) of the amyloidogenic protein 
transthyretin (TTR) with the integrin binging sequence RGD from 
fibronectin. In addition to the RGD modified sequence two 
similar sequences were synthesised with additional tripeptides 
that have no reported biological activity (RAD and RGE). All three 
peptides retained their ability to form amyloid fibrils and 
supported cell growth when fibroblasts were cultured on 
adsorbed networks of the fibrils. Only the RGD presenting fibrils 
was able to disrupt fibroblast cell adhesion to a fibronectin 
coated substrate. This suggests that the RGD modified fibrils can 
competitively bind to integrin assemblies present on the cell 
membrane.308 The biocompatibility of these modified TTR105-115-
RGD fibrils has been further explored using a number of 
membrane integrity and apoptotic markers.416 Despite good 
cellular attachment (via specific RGD-integrin bonds), the 
materials were found to show fibril morphology and 
concentration dependent cytotoxicity after longer periods of 
time. Studies such as this highlight the importance of fully 
understanding how physical, morphological and chemical 
properties of amyloid based materials affect cellular interactions 
before they can be applied as biomaterials. In addition to TTR105-
115-RGD an analogous amyloidogenic peptide was synthesised 
with a more physiological cyclic RGDfK sequence attached 
(TTR105-115-cRGDfK). Compared to the TTR105-115-RGD fibrils the 
TTR105-115-cRGDfK fibrils were seen to significantly promote cell 
adhesion and cell spreading through the development of integrin 
mediated focal adhesions between the cRGDfK ligands and the 
cell membrane.307, 417 However, masking of the cRGDfK chemistry 
with a thin plasma polymer layer revealed that the addition of 
the bulky cRGDfK sequence results in nanofibrils with a 
topography less favourable to cell growth.417 Thus, once again 
this highlights the importance of considering both chemical and 
topographical features when designing amyloid based 
biomaterials. In another interesting recent example, RGD-
functionalized PAs have been used to create enzyme (matrix 
metalloprotease)-triggerered releasable free-standing collagen-
rich films, produced by human stromal corneal fibroblasts.418, 419 
The PA coating was aligned by use of a lithographic process and 
this led to aligned collagen deposition, mimicking the alignment 
of collagen fibres in the cornea. 
 
Fig. 29 Amyloid hydrogels for cell culture: (a) Schematic of amyloid 
hydrogels for 2D and 3D cell culture. (b) Schematic of the morphology of 
cells at each stage during the implantation. Stage 1: cultured cells for 24 h; 
stage 2: cells were primed with differentiation medium for 5 days; stage 3: 
cells then transplanted with hydrogel A5 into the mice brains, and stage 4: 
harvested brains. Scale bars: 200 µm for stage 1-3 and 100 µm for stage 4. 
(c) Implanted GFP-hMSCs with α-synuclein hydrogel (left) and without 
hydrogel (right) at the caudate putamen after 7 days in vivo. (d) Cell 
viability when implanted with and without hydrogel. (e) Box plot of the 
area with survived cells when transplanted with and without hydrogel. 
Reproduced with permission from Ref. 422. Copyright 2016, Nature 
Publishing Group. 
 3D scaffolds based on amyloid nanofibril systems 
functionalised with cell adhesion moieties have also been used as 
biomaterials that promote cell growth. Zhou et al. created 
hydrogels from a mixture of Fmoc-FF and Fmoc-RGD.420 The rapid 
gelling system promoted the adhesion and 3D cell culture of 
encapsulated dermal fibroblasts through specific interactions 
with integrins on the cell membrane. Furthermore, by adjusting 
the ratios of Fmoc-FF and Fmoc-RGD in the system the 
concentration and ligand spacing of the RGD moieties in the 
hydrogel could be accurately controlled. Based on a similar 
gelation mechanism, a series of peptides based on A were 
combined with Fmoc protecting groups.19, 421 By adjusting the 
peptide sequence, concentration and the ionic strength, the 
mechanical properties of the formed gels could be controlled, 
which in turn was used to drive stem cell differentiation. In a 
similar study, Das and co-workers synthesized a new class of 
implantable α-synuclein-inspired peptide hydrogels with the 
ability to direct stem cell differentiation in vivo (Fig. 29a).422 
Mesenchymal stem cells (MSCs) were seeded into an α-synuclein 
based peptide hydrogel and transplanted into the brains of mice 
(Fig. 29b). After 7 days in vivo, the brains were harvested and 
sectioned and the cells implanted within the hydrogel showed 
increased evidence of neuronal differentiation compared to cells 
transplanted in the absence of the hydrogel (Fig. 29c). 
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Furthermore, the presence of the hydrogel resulted in increased 
cell number both within the caudate putamen (Fig. 29d) and 
substantia nigra of the implanted mice (Fig. 29e).  
 The section above highlights the considerable amount of 
research that has gone into designing bespoke amyloidogenic 
peptide sequences that self-assemble and display specific cell 
adhesion moieties on their surface. However, the design and 
synthesis of such sequences is non-trivial, and relatively 
expensive. Therefore, a different approach has also been 
investigated whereby inexpensive and abundant raw materials 
that are easily applicable to scale up to clinically relevant volumes 
required in the biomedical industry are used for the formation of 
amyloid based scaffolds. Healy et al. extracted crystalline 
proteins from fish eye lenses and studied the influence of 
temperature on their self-assembly into amyloid fibrils.423 
Furthermore, these fibrils were shown to be stable over a wide 
range of pH, over long periods of time and showed no significant 
cytotoxicity to Hec-1a endometrial cells.424 This preliminary work 
suggests that crystalline nanofibrils should be further 
investigated as 2D or 3D biomaterials. Reynolds et al. fabricated 
amyloid fibril networks from lysozyme on solid supports with 
well-defined nanoscale surface features reminiscent of the 
topography of the ECM.425 By masking the surface chemistry of 
the fibril networks with a thin layer of inert oligo (ethylene glycol) 
plasma polymer, they proved that the ECM mimicking 
nanotopography alone was enough to promote the attachment 
and spreading of a fibroblast cell line. In a following study, they 
showed that the attachment, spreading and cytoskeletal tension 
of cells could be controlled by adjusting the surface coverage of 
the amyloid fibril networks both in the presence and absence of 
serum proteins.426  
 Li et al. fabricated poly(N-isopropylacrylamide) (PNIPAM)-
decorated amyloid fibrils from -lactoglobulin. These decorated 
fibrils underwent a sol-gel transition below body temperature (32 
°C).427 This hybrid could be used as an injectable material at room 
temperature, while turning into a gel at body temperature. This 
finding may contribute to designing thermally controlled “smart” 
scaffolds for tissue regeneration applications. 
  
5.3 Energy materials  
The unique physiochemical properties of amyloid fibrils make 
them attractive materials not just in biomedical and regenerative 
medical fields. For instance, amyloid fibrils have been 
investigated as potential materials for next generation energy-
harvesting devices,428, 429 Lithium ion batteries,23, 430 organic solar 
cells,431 photovoltaic,432 and catalyst materials.316, 433  
 Hanczyc et al. showed that amyloid fibrils of insulin, lysozyme 
and α-synuclein specifically enhance multiphoton absorption.428 
Channon et al. demonstrated a detailed mechanism of the light-
harvesting function resulting from co-assembly of two 
independent luminescent moieties into amyloid-like fibrils.429  
 Similarly, light-harvesting peptide nanotubes were 
synthesized by the co-assembly of FF and porphyrin (Fig. 30a).434 
The dipeptide assemblies and porphyrin molecules mimicked the 
electron separator and mediator in natural photosynthetic 
systems, respectively. By incorporating PtNPs onto the surface of 
the FF/porphyrin nanotubes, self-metallization of PtNPs occurred, 
enabling an efficient separation and transfer of the exited 
electrons from the porphyrin to an electron mediator.  
 
Fig. 30 (a) Biomimetic photosynthesis by light-harvesting peptide 
nanotubes. Reproduced with permission from Ref. 434. Copyright 2012, 
Wiley-VCH Verlag GmbH & Co. (b) Schematic diagram of the hybrid 
photovoltaic device prepared using an active layer composed of TiO2-
hybrid nanowires blended with polythiophene and AFM image of TiO2 
decorating the surface of the amyloid fibrils. Reproduced with 
permission from Ref. 432. Copyright 2012, Wiley-VCH Verlag GmbH & 
Co. 
 The Park group performed studies on the biomimetic 
mineralization of FePO4 and Co3O4 nanoparticles on self-
assembled diphenylalanine nanofibrils23 and nanotubes.430 
They found that biomimetic inorganic-organic hybrid 
nanomaterials could act as promising cathode materials for 
rechargeable Lithium ion batteries with a high reversible 
capacity and good capacity retention during cycling. 
 Inganäs et al. demonstrated the integration of amyloid insulin 
nanofibrils into organic solar cells to enhance the transport 
properties of photovoltaic devices.431 They found that the 
amyloid nanofibrils had a significant effect on the donor-acceptor 
material organization. At a specific ratio of nanofibrils, donors 
and acceptors the hybrid organic solar cells showed improved 
charge transport compared to the materials without added 
nanofibrils. 
 Bolisetty et al. utilized β-lactoglobulin amyloid fibrils as 
templates to successfully direct the synthesis of closely packed 
TiO2 hybrid nanowires.432 Due to the well-organized combination 
of electrostatic and hydrogen bond interactions, TiO2 
nanoparticles decorated the surfaces of the protein fibrils 
uniformly. Subsequently, the TiO2-coated amyloid hybrid 
nanowires could be prepared into a photovoltaic active layer by 
spin coating a blended mixture of polythiophene-coated fibrils 
and amyloid-TiO2 hybrid nanowires (Fig. 30b). Acar et al. 
demonstrated the amyloid peptide nanofibril templated 
synthesis of TiO2 nanostructures via a bottom-up approach.435 By 
staining the calcinated TiO2 layer with an N719 photosensitizer 
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dye, they fabricated dye sensitized solar cells with high loading 
capabilities, and improved open circuit voltages exploiting the 
high surface area offered by the amyloid fibrils. 
 Amyloid fibrils also have important potential applications in 
heterogeneous catalysis. Bolisetty et al. prepared AuNPs and 
PdNPs respectively on β-lactoglobulin amyloid fibrils for catalytic 
reduction of 4-nitrophenol.316 In another study, Chaves et al. 
reported a new biocatalyst based on the photo-immobilization of 
lipase onto amyloid fibrils via a photo-induced cross-linking 
reaction.433 The resulting insoluble nanoscale biocatalyst showed 
higher enzyme stability than the soluble enzyme under several 
extreme conditions. Scott and co-workers demonstrated the 
preparation of amyloid (Fmoc-FF) peptide gel microparticles that 
are emulsified and stabilized with SiO2 nanoparticles.436 The 
amyloid matrix was used to immobilise the enzyme lipase B (CalB) 
and the catalytic performance assessed by monitoring the 
esterification of octanol in heptane. In the best performing 
system, the authors observed almost a 4-fold increase in catalytic 
activity compared to native CalB. Bio-catalytic amyloid 
microparticles such as these could be very useful for fabricating 
biosensors and bioinspired solar fuel devices. 
 
5.4 Environmental science and technology 
Amyloid fibrils have also found important applications in the 
environmental sciences. For instance, Bolisetty and Mezzenga 
reported that inexpensive and environmentally friendly β-
lactoglobulin amyloid fibrils could be blended with activated 
carbon and filtered to form membranes capable of purifying a 
variety of contaminants from wastewater samples.118 The initial 
study showed that these simple membranes provided 
remarkable levels of purification for water samples containing 
heavy metal, organic, and bacterial contamination. As shown in 
Fig. 31a, heavy metal ions purification occurred due to the 
presence of metal ion binding sites on the surface of the amyloid 
fibrils. After filtering, the content of potassium dicyanoaurate (I), 
mercury chloride and several other tested pollutants, was 
reduced by nearly three orders of magnitude (Fig. 31b and c). 
Leung et al. modified lysozyme amyloid fibrils with 
ethylenediamine to reduce their carboxyl content enabling the 
adsorption of toxic chromium(VI) ions in water.437 These studies 
open up new possibilities in fabricating functionalised amyloid 
based materials that can efficiently scavenge pollutants from 
water supplies.  
 
Fig. 31 Amyloid nanofibril-based materials for water purification. (a) 
Structure of the β-lactoglobulin protein with the heavy metal-binding 
motif highlighted, 121-cys, with a lead ion attached and the 121-cys-
containing fragment (LACQCL) from β-lactoglobulin with docked Pb2+. 
(b,c) Concentrations of heavy metal and radioactive pollutants before 
and after filtration through the amyloid fibril-activated carbon hybrid 
adsorber membrane: (b) Potassium dicyanoaurate (I); (c) Mercury 
chloride. Reproduced with permission from Ref. 118. Copyright 2016, 
Nature Publishing Group. 
 In a similar manner to the scavenging of waterborne 
contaminants outlined above, amyloid based materials could 
have applications as materials for capturing carbon dioxide from 
the atmosphere, thus helping to address the global threat of 
climate change. Li and co-workers reported that amyloid fibrils 
formed from the peptide sequence VQIVYK were capable of 
sequestering CO2.438 They found that the ε-amino group of lysine 
is uncharged at a high pH, which is thus capable of forming 
carbamate with atmospheric CO2. The materials were able to 
capture CO2 in the presence of water, which was later released 
by heating. In a further study, the same authors used VQIVYK 
capped with N-terminal acetylation and C-terminal amidation to 
increase fibril formation and promote the diffusion of small 
gaseous molecules.439 Binding of carbon dioxide is thought to 
occur via carbamate formation with amine functional groups 
present in the lysine residues. In another design, they mutated 
the glutamine residue in position 2 to lysine, generating the 
hexapeptide VKIVYK.438, 439 Although there was twice the number 
of amines in the designed fibrils, a two-fold increase in binding 
capacity of CO2 was not observed, indicating that in these fibrils 
the amine groups are only partially accessible.  
  
5.5 Electronic nanodevices 
Inspired by the high efficiency of charge transport in biological 
systems, the possibility of introducing charged proteins and 
peptides in electronic devices has been suggested.440 The unique 
hybrid conductivity behaviour makes self-assembled peptide 
nanostructures powerful building blocks for the construction of 
electronic nanodevices.441 Carny et al. fabricated coaxial gold 
and silver nanocables by binding metallic NPs onto the self-
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assembled peptide nanotubes via molecular recognition.442 
Dinca et al. successfully fabricated 3D structures from amyloid 
fibrils with potential application in molecular electronics.443, 444 
Amit et al. studied the conductance of the thiophene 
containing peptide (2-Thi) (2-Thi) VLKAA under a range of 
humidity conditions.445 They found that the conductivity of the 
fibrils was increased at higher relative humidity, indicating proton 
transport rather than electron transport dominates the 
conductive behaviour. Compared with amyloids from the 
naturally occurring peptide AAKLVFF, the conductance of (2-Thi) 
(2-Thi) VLKAA was found to be much higher, and this was 
attributed to subtle changes in the folding structure. 
 
Fig. 32 Fabrication of amyloid-based transistors. (a,b) PEDOT-S amyloid 
nanofibrils based transistor: (a) molecular structure and (b) schematic 
picture the electrolyte gated transistor. Reproduced with permission 
from Ref. 446. 2008, American Chemical Society. (c,d) Amyloid-PAni 
hybrid nanofibril-based transistor: (c) synthesis and AFM image of PNF-
PAni hybrid fibrils and (d) deposited hybrid fibrils on gold electrode array 
for conductivity measurements (PNF: peptide nanofibrils). Reproduced 
with permission from Ref. 447. Copyright 2015, American Chemical 
Society. 
 Self-assembled amyloid nanofibrils have found applications 
as building blocks for electrochemical transistors.440 For instance, 
Hamedi et al. designed amyloid insulin fibrils coated with the 
highly conducting polymer alkoxy sulfonate poly(3,4-
ethylenedioxythiophene) (PEDOT-S).446 The assembled network 
was dispersed in an acetonitrile electrolyte and probed with a Pt 
gate electrode (Fig. 32a and b). The fabricated amyloid-PEDOT-S 
transistor showed high source-drain currents and also displayed 
repeatable switching characteristics with an on/off ratio of >40 
when sweeping the gate between 0 and 0.5 V, clearly showing 
that PEDOT-S has not lost any electrical or electrochemical 
properties after self-assembly with amyloid fibrils. Furthermore, 
the nanowire networks showed ohmic connection to the metal, 
and no detachment during the electrochemical reactions. Meier 
et al. prepared conducting polyaniline (PAni) nanowires with a 
core-shell structure using amyloid nanofibrils as a template.447 
Adsorption of the conducting polymer to the fibrils was 
facilitated through binding between the hydrophobic aromatic 
functional groups on the PAni, and the exposed hydrophobic 
pockets on the surface of the growing fibrils (Fig. 32c). The 
resultant materials were deposited on an array of gold electrodes, 
as shown in Fig. 32d. The conductivity of coated hybrid fibrils was 
found to be far higher than that of uncoated fibrils. In another 
study, Tu and co-workers reported the fabrication of an 
electrochromic transistor based on PEDOT-decorated amyloid 
fibrils.448 These studies show that amyloid fibrils provide an 
excellent structural template for the directed deposition of 
conducting polymers, which has major potential applications in 
the fabrication of next generation microelectronic devices. 
 Amyloid fibrils also exhibit promising electronic applications 
as organic light-emitting diodes (OLEDs).449-453 For instance, 
amyloid insulin fibrils were conjugated with luminescent 
conjugated polymers, and used as the active layer in an OLED 
device.449, 450 The introduction of amyloid fibrils into the 
fabricated OLED device resulted in a 10-fold increase of the 
external quantum efficiency.450 In other studies, the same 
amyloid fibrils were functionalized with phosphorescent 
organometallic (Ir) complexes to fabricate red and yellow 
OLEDs.451, 452 The conjugation of phosphorescent organometallic 
complexes with amyloid structures was seen to strongly improve 
the triplet exciton confinement and make it possible to fabricate 
white-emitting devices at low loading of phosphorescent 
complexes. More information on the modification of amyloid 
fibrils, as well as the fabrication and applications of OLEDs with 
fibrils have been discussed in a recent review article.453 
 
5.6 Biosensor architectures 
Amyloids have been shown to have promising applications in the 
design of novel biosensors. This is in part due to their high 
mechanical strength and chemical resistance to the surrounding 
milieu, their ability to detect nanoscale protein-ligand 
interactions and selectivity for low concentrations of biomolecule 
analytes.454 For instance, self-assembled amyloid peptide 
nanotubes have been utilized to create novel electrochemical 
biosensing platforms for detecting hydrogen peroxide and 
enzymes.455, 456 
 Amyloids functionalized with ligands such as fluorophores, 
antibodies or enzymes can also be used for biosensing 
applications.457 Glucose oxidase (GOx)-functionalized whey 
protein nanofibrils (WPNFs) were seen to promote the enzyme 
immobilization on screen-printed gold electrodes due to the 
large surface-to-volume ratio of the WPNF nano-scaffold.458 
Compared to simple physical enzyme adsorption, the produced 
cyclic voltammogram exhibited a distinct increase in the anodic 
peak current response when using WPNF nano-scaffolds. The 
anodic peak currents were even larger when using the thiol-
functionalized WPNFs, due to increased binding of WPNF on the 
gold surface.  
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Fig. 33 Amyloid protein nanofibril-based immunosensors. (a) 
Schematic synthesis of Sup35-BAP nanofibrils. (b) Fabrication of 
immunosensor architecture via biotin-streptavidin interaction. (c) 
Improved sensing performance compared to non-fibril sensors. 
Reproduced with permission from Ref. 459. Copyright 2010, Elsevier 
Ltd. 
 Amyloid protein nanofibrils have shown potential for the 
fabrication of enzyme-linked immunosorbent assay (ELISA) 
immunosensors.459, 460 For instance, Men and co-workers 
demonstrated the design of an auto-biotinylated bifunctional 
protein nanowires (bFPNw) based on the self-assembly of 
recombinant biotin-modified amyloid protein Sup35 (Fig. 33a).459 
The high concentration and regular arrangement of biotin 
molecules on the surface of the bFPNws allows any of the 
hundreds of commercially available diagnostic enzymes to be 
transferred to the surface of the immunosensor via the biotin-
avadin reaction (Fig. 33b). These biosensors were able to detect 
Yersinia pestis F1 antigen with a 2000- to 4000-fold increase in 
sensitivity compared to traditional ELISAs (Fig. 33c). In addition, 
the bFPNw-based system was seen to amplify the detection 
signal, reduce the non-specific binding, and improve stability. In a 
similar example, gene fusion was used to express recombinant 
Sup35-E2-GFP-MPH where E2-GFP-MSH is fluorescent biosensor 
based on green fluorescent protein linked to the enzyme methyl 
parathion hydrolase. The self-assembled nanofibrils were able to 
detect the pesticide methyl parathion with a sensitivity around 
10,000 times greater than free E2-GFP-MSH.460  
 
Fig. 34 Amyloid nanofibril-GO shape-memory materials. (a) Fabrication 
mechanism, (b) AFM of nanofibril-GO hybrid, (c) SEM image of 
nanofibril-GO hybrid film, and (d) Biosensors for enzymatic activity 
measurement. Reproduced with permission from Ref. 20. Copyright 
2012 Nature Publishing Group. 
 Whilst gene fusion approaches such as those discussed above 
certainly show great promise for the design of amyloids that can 
act as enzymatic biosensors, their complexity and the specialised 
expertise required for their development may hinder their 
development. As an alternative amyloid β-lactoglobulin nanofibrils 
were combined with GO to fabricate biodegradable 
nanocomposites with shape-memory and enzymatic sensing 
properties20 Free-standing nanofibril-RGO films were fabricated in a 
series of steps: after assembly of the fibrils and binding of the fibrils 
to the GO sheets, the GO sheets were reduced at high 
temperatures to RGO. RGO-fibril films were formed by vacuum 
filtration, as shown in Fig. 34a and b. The free-standing hybrid 
nanocomposite films possessed a film thickness of 40-60 µm (Fig. 
34c) and displayed a remarkable and fully reversible shape-memory 
effect. In addition, the nanocomposites could be totally degraded 
by simple enzymatic reactions, or, under controlled enzymatic 
reactions, be used as a new class of biosensors to measure 
enzymatic activity (Fig. 34d). 
   
5.7 Other functional nanomaterials 
Besides the above mentioned biomedical and nanotechnological 
applications, amyloids fibrils have been used for the fabrication of 
other novel functional nanomaterials including liquid crystal 
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materials,298, 461-465 photoluminescence and optical waveguiding 
materials.466-468  
 The formation of liquid crystal phase by amyloid fibrils is 
important for the fabrication of nanomaterials with hard structures, 
which could be reinforced by the rigid and anisotropic amyloid 
fibrils. Suspensions of amyloid fibrils frequently form liquid crystal 
phases due to long range non-covalent interactions between 
assemblies. 160, 321-325 For instance, Corrigan et al. demonstrated that 
the lysozyme nanofibrils readily form liquid crystal phases.462 Zhao 
et al. created amyloid fibrils suspensions with isotropic-nematic 
coexistence by freeze-thaw cycling.463 Han and co-workers found 
that FF rapidly self-assembles into nanowires with high aspect ratio 
in a volatile organic solvents, which showed a colloidal nematic 
liquid crystalline phase over a broad concentration range.464 Hamley 
and co-workers  showed that AAKLVFF nanotubes465 and helical 
peptide βAβAKLVFF ribbons,298 and other amyloidogenic peptides 
can form nematic liquid phases in organic solvent and water, 
respectively.  
 Self-assembled amyloids have been used for the synthesis of 
bioinspired functional materials for optical waveguiding. Ryu et al. 
reported the in situ conjugation of self-assembled FF nanotubes 
with the photosensitizers (4-acetylbiphenyl) and lanthanide (Tb3+ 
and Eu3+) ions for fabricating novel photoluminescent nanotube 
materials.466 Their finding indicated the FF nanotubes acted not 
only as a host matrix for lanthanide complexes, but also served as a 
photosensitizer. By careful adjustment of the composition of 
lanthanide complexes, various nanotubes with switchable colours 
(red, green, blue, cyan, and purple) were fabricated. In another 
study, Yan and co-workers demonstrated the optical waveguiding of 
self-assembled hexagonal FF microtubes and FF fibrous networks.467, 
468 The fabricated peptide nanotubes exhibited remarkable thermal 
stability and optical waveguiding, making them novel candidates to 
design and develop optical and electrical nanodevices.  
  
6 Conclusions and outlook  
In this review, we summarized the recent progress in both the 
fundamental study and applications of amyloid systems. We 
focused on the elucidation of the self-assembly mechanisms, 
hierarchical structure, physical properties of a series of 
amyloid nanostructures from molecular oligomers to 0D, 1D, 
2D, and 3D nanomaterials. We elaborated on how the 
understanding at a very fundamental level of these salient 
features illuminates their application on the most diverse 
areas of artificial and biological materials. A wide range of 
strategies for fabricating natural and artificial amyloid-based 
materials were discussed. In addition, the various applications 
of amyloid-based hybrid nanomaterials for biomedical 
engineering, tissue engineering, energy materials, 
environment science, nanodevices, biosensors, and others 
were introduced and discussed in detail.  
 Looking to the future there are some areas which would 
benefit further research. More work should be focused on 
using computer simulation techniques such as molecular 
dynamics in order to understand the molecular mechanisms 
underpinning the formation of amyloid oligomers and other 
intermediates. Secondly, work should be performed to 
elucidate the selection rules and mechanisms responsible for 
the creation of 2D and 3D amyloid based materials. 
Multidimensional amyloid based nanomaterials show many 
promising applications for materials science and 
nanoelectronics. Currently, the controllable growth and 
formation of 2D and 3D amyloid structures is challenging and 
very difficult to predict due to a lack of fundamental 
knowledge. Thirdly, the exploitation of functional motifs from 
amyloid proteins to create biofunctional-specific amyloid 
nanostructures should be further investigated. In addition, it is 
possible to endow other functions like material recognition, 
biomineralization, and cell adhesion to the created amyloid 
nanostructures by inserting additional peptide motifs. Last but 
not least, it is to be hoped that the biocompatibility, 
biodegradation, and cellular toxicity of amyloid materials will 
be understood and tailored to a greater extent, as this could 
potentially unlock an extraordinary large numbers of 
applications in the field of biotechnologies and biomaterials. 
 In this respect, the contrast between the disease-relevant 
instances of amyloids and the various applications of amyloid-
derived materials in a biological context, deserves some 
discussion, as this raises the question of the potential safety 
challenges of such materials. In general, the main discriminant 
in the selection of the amyloid building blocks should be the 
chemical nature of the peptides or proteins forming the 
amyloids. When the primary structure of the peptide/protein 
building block contains motifs from pathologically relevant 
amyloid-forming peptides, potential dangers need to be 
carefully considered up-front, although there are also 
examples where amyloids fibrils composed from fragments 
derived from pathological amyloidogenic proteins have been 
successfully used as cell scaffolds.308 A very recent study, 
however, clearly points to a safe use of amyloid fibrils in-vivo -
even in the context of food applications- when the fibrils are 
composed of hydrolyzed edible proteins.469 Shen et al. have 
indeed used hybrids of β-lactoglobulin amyloid fibrils and iron 
nanoparticles to design a new efficient colloidal form of highly 
bioavailable nano-sized iron to be used in anemia 
treatment.469 The trick used by the authors is to exploit the 
combined acidic and enzymatic environment present in the 
stomach to allow a fast dissolution of both the amyloid fibrils, 
digested by pepsin, and the iron nanoparticles, dissolved by 
the acidic pH, leading to a rapid dissolution of these hybrids 
into hydrolyzed milk proteins and highly bioavailable iron ions. 
This work convincingly demonstrates that if amyloid fibrils are 
made of edible building blocks and are administered through 
the gastrointestinal tract to enable correct digestion, they 
could even revolutionize fields such as pharmaceutics, food 
technology and nutrition, in which amyloid fibrils were never 
used before, tremendously widening the scope of applications 
of these fascinating materials. 
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